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ABSTRACT 
Melanoma is considered as one of the most aggressive forms of skin cancer and 
treatment is unsuccessful due to development of resistance. The complexity and different 
genetic alterations of melanoma makes it difficult to target. Therefore, finding the right 
treatment combination, attacking several signaling pathways at the same time might improve 
patient survival. 
To understand melanoma progression and metastasis it is necessary to have insight 
into signaling pathways and their downstream effectors, such as p21 (WAF1/Cip1), a 
regulator of cell cycle progression. p21 is often deregulated in human cancers and has 
previously been shown to induce growth arrest/senescence. In the present study, we 
investigated the expression and regulation of p21 in a melanoma cell line panel consisting of 
17 cell lines. We found a strong correlation between p21 mRNA and protein levels in all cell 
lines, except for the LOX cell line. We then correlated p21 expression levels against the 
progression of melanoma without detecting any obvious pattern. Furthermore, we detected a 
strong correlation between p21 expression levels and the p53 status in all of the cell lines. The 
correlation between p53 and p21 was also found after treating A375 and SKMEL28 with 
inhibitors against the MAPK- and cAMP-pathways. These latter results suggest that p21 is 
tightly controlled by the p53 tumor suppressor gene. However, p21 expression has also been 
shown to be regulated independently of p53. To address this, we investigated the expression 
of a number of transcription factors that previously have been reported to bind to the p21 
promoter. When comparing these expression levels with p21 expression we did not find any 
obvious correlation, either positve or negative. The role of p53-independent transcriptional 
regulation of p21 is not fully understood and further studies needs to be carried out to disclose 
its role. 
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ABBREVIATIONS 
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Protein kinase B (PKB) 
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Human epidermal growth factor receptor 1 
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CDC6 Cell division cycle 6 
CDKN1A 
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CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
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CREB cAMP responsive element binding protein 
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ERK Extracellular signal-regulated kinase 
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FEMX-I 
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Wistar institute melanoma cell line number 45.1 
Human melanoma cell line 
Human melanoma cell line 
Human melanoma cell line 
Human melanoma cell line 
Human melanoma cell line 
MAPK 
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Mitogen-activated protein kinase 
Mitogen-activated protein kinase (MAPK) signal transduction cascade 
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mTOR Mechanistic target of rapamycin 
MYC 
MOPS 
mRNA 
NRAS 
nt 
p16 
p21 
p-AKT 
p-ERK1/2 
p-AMPK 
p-CREB 
p-STAT1 
PCR 
PLX 
UO126 
H-89 
BI-D1870 
v-myc avian myelocytomatosis viral oncogene homolog 
3-(N-morpholino) propane sulfonic acid 
Messenger RNA 
Neuroblastoma ras viral oncogene homolog 
Nucleotides  
Cyclin-dependent kinase inhibitor 2A (p16) (CDKN2A) 
Cyclin-dependent kinase inhibitor 1A (P21, WAF1, CIP1) (CDKN1A) 
Phosphorylated AKT 
Phosphorylated ERK1/2 
Phosphorylated AMPK 
Phosphorylated CREB 
Phosphorylated STAT1 
Polymerase chain reaction 
Plexxikon, vemurafenib 
Mek1/2 inhibitor 
PKA inhibitor 
RSK inhibitor 
PEA3 Ets variant 4 (ETV4) 
PI3K Phosphatidylinositol-3 kinase 
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SECTION I: INTRODUCTION 
1.1 Cancer 
Cancer is a genetic disease involving unregulated cell growth and cell divisions, 
forming malignant tumors, invading nearby tissues, and metastasizes to distant organs [1]. 
This disease is responsible for one in eight deaths throughout the world [1, 2]. It is known that 
cancer is difficult to treat and cure due to its genetic complexity and heterogeneity [2, 3]. 
Somatic mutations (such as point mutations, insertions and deletions of bases), DNA 
rearrangements (caused by DNA breakage), copy number changes (of DNA segments) and 
epigenetic alterations contribute to the complexity and heterogeneity of cancer [3, 4]. In 
general, no single mutation can cause cancer alone, but multiple mutations in key regulatory 
genes may put the cell at risk [5]. The tumor microenvironment (consisting of neighboring 
blood vessels, immune cells, fibroblasts, signaling molecules, the extracellular matrix (ECM) 
and other cells) have also been found to affect the process of tumor initiation, growth, 
progression and metastasis [6]. Deregulated signal pathways in and around tumor cells, as 
well as the absence of many regulatory checkpoints results in aberrant uncontrolled growth. A 
set of phenotypic properties essential for cancer development termed the hallmarks of cancer 
have been proposed by Hanahan and Weinberg (2011) and are presented in figure 1.1.  
 
Figure 1.1. The hallmarks of cancer. The figure is reproduced with permission from Hanahan 
and Weinberg, 2011 [6]. 
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Mutations promoting one (or multiple) of these hallmarks make the cell more likely to 
persist, survive, and divide uncontrolled [7]. Indeed, it is indicated that no two cancers are 
identical at the molecular level and that different cancers have diverse response to therapy [3, 
8]. 
 
1.2 Melanoma 
Melanoma is an aggressive form of skin cancer originating from melanocytes found in 
the skin and eyes. Skin is made up of two main layers: the epidermis (outer layer of skin) and 
the dermis (inner layer of the skin). The deepest layer of the epidermis, just above the dermis, 
contains melanocytes. The melanocytes can differentiate from embryonic stem cells and are 
responsible for producing the pigment melanin that plays a role in coloration of skin for 
protection against UV radiation [9]. Melanoma is considered to be the deadliest form of skin 
cancer and is known for its resistance to conventional therapy. However, development of 
novel personalized targeted therapy strategies may bring new hope [10-12]. An estimated 
number of 166.900 patients were diagnosed with melanoma in developed countries in 2011 
[13]. According to the Cancer registry of Norway, melanoma is one of the most common 
types of cancer in Norway, with an increasing rate of incidence and mortality of 1718 and 325 
in 2011, respectively [14]. Thereby, Norway is one of the countries with highest incidence 
and mortality rates of malignant melanoma in Europe [15]. Exposure to ultraviolet (UV) 
radiation from the sun, which makes alterations in the genome is a major risk factor for 
development of melanoma [9, 10]. People exposed to bright sunlight year-round, people who 
use tanning beds, those with fair skin and moles, and people with family disease history have 
an increased risk of developing melanoma. [15, 16].  
 
1.2.1 Melanoma tumor progression 
Melanoma can occur anywhere in the body where melanocytes (melanocytes are 
derived from the neural crest during development) are found. Melanoma begins when normal 
melanocytes change and grow uncontrollably, forming a mass called a tumor. A tumor can be 
benign (noncancerous) or malignant (cancerous, meaning it can spread to other parts of the 
body). The tumor progression from melanocyte to melanoma is illustrated in figure 1.2. 
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Figure 1.2. The figure shows the steps of melanoma progression. 1) Benign nevus 2) 
Dysplastic nevus 3) Radial-growth phase 4) Vertical-growth phase 5) Metastatic melanoma. 
The figure is reproduced with permission from Miller and Mihm, 2006 [17]. 
The steps of tumor progression from normal melanocyte to melanoma are as follows:  
1) Mutations in normal melanocytes form benign nevus in epidermis.  
2) Abnormal growth of melanocytes in a pre-existing nevus or new location resulting in a pre-
malignant lesion, dysplastic/atypical nevi.  
3) Radial growth: melanocytes acquire ability to proliferate horizontally in the epidermis 
(non-tumorigenic primary melanomas without metastatic competence).  
4) Vertical growth: numerous biochemical events allow malignant cells to invade basement 
membrane and proliferate vertically in the dermis with metastatic potential (tumorigenic 
primary melanomas with competence for metastasis).  
5) Metastasis: malignant melanocytes spread to other areas of the body by entering blood or 
lymphatic vessels and form tumors at distant sites. Spreading occurs usually first to lymph 
nodes, then to skin, subcutaneous soft tissue, lungs and the brain [17, 18]. 
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1.2.2 Melanoma metastasis 
The most dangerous aspect of melanoma is its ability, in later stages, to spread (or 
metastasize) to other parts of the body. The spread occurs through the lymphatic system 
and/or the blood vessels. Melanoma can spread to the subcutaneous tissue which lies 
underneath the skin, the lymph nodes, and to other organs such as the lungs, liver, to bone or 
to the brain [19]. Metastasis is typically described as a multistep process involving tumor cells 
ability to invade normal surrounding tissue through entering the blood circulation. The other 
steps of the metastasis include tumor cells which can adhere, extravagate, survive, and grow 
in the target organ [20, 21]. In order for a tumor cell to metastasize and form a clinically 
detectable and potentially lethal metastasis, it must complete a series of steps which is 
presented in figure 1.3. 
 
 
Figure 1.3. The figure shows metastatic process of melanoma. The formation of a primary 
tumor is followed by tumor cells that are able to enter into the lymphatic vessels. Tumor cells 
then travel to the lymph node and subsequently enter into the systemic circulation via the 
thoracic duct. After that, tumor cells need to be able to survive in the circulation and they 
must adhere to the microvasculature of a target organ. The tumor cells then extravagate, and 
subsequently proliferate in order to develop into a secondary tumor and form a clinically 
relevant metastasis. Figure reproduced with permission from Damsky and Bosenberg, 2010 
[20]. 
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The mechanisms regulating either success or failure at any step in the metastatic 
process are likely important and probably differ amongst different melanomas and different 
target organs [18, 20, 22].  
 
1.2.3 Signaling pathways relevant for melanoma development 
To understand melanoma development and metastasis it is necessary to have insight 
into signaling pathways that control proliferation and survival. Signaling pathways make 
cascades for transferring information from extracellular signals through receptors towards the 
nucleus where the expression of different genes is regulated. Complex changes in these 
pathways thus contribute to melanoma development and progression by deregulating genes 
that may lead to increased survival, proliferation, invasion, and angiogenesis [23]. The most 
prominent signaling pathways that are revealed to affect the melanoma development and 
progression are the MAPK- and PI3K/AKT-pathways, Wnt/-Catenin, and the -MSH 
signaling pathways [24]. The master regulator of melanocyte proliferation, survival and 
differentiation is Microphtalmia transcription factor (MITF). The MITF gene is strongly 
influenced by multiple upstream pathways, including c-KIT, Wnt/-Catenin, and -MSH [24, 
25]. A simplified illustration of these pathways is shown in figure 1.4. c-KIT, Wnt and -
MSH signaling cascades are shown in purple, yellow and blue, respectively. 
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Figure 1.4. The figure shows signaling pathways often dysregulated in melanoma. Activation 
of c-KIT, by the stem cell factor (SCF) receptor tyrosine kinase triggers many downstream 
events, including activation of the MAPK and PI3K pathways. Activation of the Wnt/ -
Catenin pathway results in the stabilization and nuclear translocation of -Catenin. 
Activation of -MSH/cAMP pathway results in MITF promoter activation. Activated MITF 
can then regulate a vast number of genes, including p21. Figure adapted and reproduced with 
permission from Hocker and Sing, 2008 [24]. 
It is believed that deregulation of the PI3K/AKT-pathway, along with a constitutively 
active MAPK-pathway, promotes the development of melanoma by increasing cell 
proliferation and enhancing the resistance to apoptosis [23, 26]. 
  
1.2.4 Genetic alterations in melanoma 
Understanding the molecular genetics underlying melanoma development and 
progression is necessary in order to develop rational treatments for the disease. Melanomas 
that occur in humans are usually deregulated in the RAS pathway, either by mutations or up-
regulation of surface receptors (e.g. c-KIT and EGFR) or by mutations in intracellular 
signaling (e.g. NRAS, BRAF, and NF-1), which leads to elevated levels of activated ERK. In 
addition, mutations or epigenetically silencing of the CDKN2A (p16) gene is frequent. Since 
RAS also activates the phosphatidylinositol 3-kinase-PTEN-Akt pathway, NRAS mutations 
also results in elevated levels of activated Akt. Of note, melanoma cells have either NRAS or 
BRAF
V600E
 mutation; they are never present within the same cell. In addition to NRAS, 
BRAF, and p16 mutations, a number of other genes have been found to be mutated in 
melanoma such as, PTEN, c-KIT, p53, CDK4, MC1R, and EGFR etc. Understanding the role 
of alterations in the pathways involved in melanoma and their interactions may provide 
important information that can be used in therapeutic settings. Table 1.5 shows the frequency 
of some important genetic mutations that are occurring in metastatic melanoma tumors. 
 
Table 1.5. Genetic alterations and their incidences in melanoma tumor specimens. 
Mutation  Incidence  Reference  
BRAF
V600E
 50%  [12] 
NRAS 15-25%  [27] 
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CDKN2A (p16) 30-70% [24] 
PTEN 15-50%  [24] 
p53 13%  [24] 
c-KIT 0-39%  [24] 
MITF 
amplification 
21%  [25] 
  
1.2.5 Melanoma treatment options 
Melanoma is shown to be resistant to radiation therapy, chemotherapy and 
immunotherapy [26, 28]. Moreover, melanoma is a heterogeneous disease and the 
modifications within the tumors and metastases make it difficult to treat by targeted therapy 
[29, 30]. The study of tumor progression has been an important focus for the diagnosis of 
melanoma and is important for the prognosis prediction. If the tumor is detected at an early 
stage, before it has invaded into the dermis, it can usually be removed surgically or in 
combination with conventional chemotherapy, which provides a cure for about 99% of the 
patients [11, 31]. However, in 10% of the incidences the disease has developed into the late-
stage melanoma, which rarely responds to existing therapies [26, 32]. An overview over some 
exciting melanoma treatment options and their mechanism of actions are shown in table 1.6.  
 
Table 1.6 shows an overview over various treatment options for the melanoma disease. 
Treatment Inhibition  Reference  
Imatinib  RTK (c-KIT) [33] 
Erlotinib, gefitinib RTK (EGFR) [33] 
Trastuzumab  RTK (HER2) [33] 
Farnesyl transferase inhibitors NRAS [24] 
Rapamycin  mTOR [33] 
Sorafenib BRAF [33] 
Vemurafenib  BRAF
V600E 
[34] 
Mek inhibitors MEK [24] 
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CDK inhibitors CDKN2A [24] 
Dacarbazine (DTIC) Cell proliferation [35] 
Interleukin-2 (IL-2) IL-2 receptor, AKT [36] 
Ipilimumab  CTLA4 [36] 
 
Dacarbazine (DTIC), an alkylating agent, was until recent the standard treatment 
option for patients with advanced stage melanoma but unfortunately, the response rate for 
single agent treatment with DTIC is low (7-13%) with severe side effects [28, 31, 36]. 
Recently, approval of two promising more specifically targeted therapeutic approaches, 
ipilimumab and vemurafenib, have led to increasing understanding of melanoma 
characteristic and biology [31]. Ipilimumab is a monoclonal antibody that blocks cytotoxic T-
lymphocyte-associated antigen 4 (CTLA4) on lymphocytes and thereby stimulating the 
immune system against the cancer cells. This strategy has been associated with enhanced 
overall survival [37], but the response rate is unfortunately low [31]. Another drug, 
vemurafenib, also called plexxikon (PLX4032), is a potent kinase inhibitor that shows 
selectivity against the BRAF
V600E
 mutation. Vemurafenib has received FDA (US Food and 
Drug Administration) approval and is known to induce tumor regression in 70% of patients 
with late stage metastatic melanoma [34, 36, 38]. The BRAF
V600E
 mutation is a good 
candidate for therapy in tumors with constitutive activated and deregulated BRAF
V600E
 [39]. 
Unfortunately, the duration of the response is short and most patients develop resistance to the 
drug, which outcomes in relapse [31]. The drug resistance usually involves reactivation of the 
MAPK pathway, activation of receptor tyrosine kinases (RTKs) or activation of the 
PI3K/AKT-pathway [34]. However, ongoing studies have suggested that combination therapy 
targeting multiple pathways along with Vemurafenib may improve patients’ survival [10, 34, 
40].  
 
1.3 p21WAF1/CIP1 in melanoma 
p21 / WAF1/ CIP1 (hereafter called p21) also known as cyclin-dependent kinase 
inhibitor 1 or CDK-interacting protein 1 (CIP1) or wild-type p53-activated factor (WAF1) is a 
protein that is encoded by the CDKN1A gene located on chromosome 6 (6p21.2) in the 
human genome [41, 42]. CDK inhibitors are negative regulators of cell proliferation and are 
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often deregulated in human cancers. The p21 protein binds and inhibits the activity of 
CDK4/6 complexes, cyclin E-CDK2 and cyclin B-CDK1, and thus functions as a regulator of 
cell cycle progression at G1 and S phase [42-45]. The ability of p21 to inhibit the cell cycle 
have been shown to induce growth arrest and in some occasions senescence [46, 47]. In 
addition, p21 may function as a tumor promoting factor by preventing apoptosis [46, 47]. 
Independently of p53 status, it is reported that p21 expression is absent in 
approximately 30% and 40% of the primary and metastatic melanomas, respectively. In most 
cases, there is a good correlation between p21 mRNA and protein expression, which might 
suggest that the protein expression is mainly regulated transcriptionally [48]. 
 
1.3.1 Transcriptional regulation of p21 
The p21 promoter region 
A number of transcription factor binding sites have been found in the p21 promoter 
region (see figure 1.7). Among these are binding sites for p53, which activates p21 
transcription via two consensus binding sites located at -2285 and -1394 base pairs upstream 
from the transcription initiation site. In addition to p53, other stimuli such as growth factors, 
hormones, intracellular signaling molecules and tumor suppressors also regulate p21 
transcription.  
 
 
Figure 1.7. Schematic drawing of the p21 promoter and its different response elements. Ca, 
calcium; C/EBP, CCAAT/enhancer binding protein; IL, interleukin; INF, interferon; OA, 
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ocadaic acid; p300, cAMP-response element binding protein (CBP/p300); PMA, phorbol-12-
myristate-13-acetate; PR, progesterone receptor; RAR, retinoic acid receptor; TPA, 12-O-
tetradecanoyl-phorbol-13-acetate; TPO, thrombopoietin. The transcription factors Ap2, E2A, 
Sp1/3 and STATs are also presented. T, TATA-box; circles with an asterisk, p53-binding sites, 
which overlap distally with the Ets-binding sites; black circles, STAT-binding sites; white 
circles, Sp1 binding sites, of which the proximal five are numbered. Numbering of the base 
pairs correlates with the transcription start site at +1. Figure reproduced with permission 
from Gartel and Tyner, 1999 [49]. 
 
Known modulators of p21 expression 
Many transcription factors have been shown to regulate p21 expression, and some of 
them are presented in table 1.8. How these transcription factors and signal pathways 
coordinately regulate p21 expression in response to intrinsic and extrinsic signals in 
melanoma is however not fully understood.  
 
Table 1.8. Transcription factors regulating p21 expression. 
Modulators Effect on p21 Cancer type  Reference  
ELK1 Activator Colon cancer [42] 
ELK4 Activator Prostate cancer [50] 
PEA3 Activator Oesophageal adenocarcinoma [51] 
E1AF Activator Cervical cancer [52] 
ETS1 Activator Vascular smooth muscle cells [53] 
ETS2 Activator Fibroblast and the mink lung 
epithelial cells 
[54] 
AP-1 (JunB) Activator Endometrial cancer [55] 
AP-2 (TFAP2A/C) Activator Colorectal cancer [56] 
C/EBPα Activator Hepatocytes  [57] 
C/EBPβ Activator Colorectal cancer [58] 
p300 Activator Osteosarcoma  [59] 
NF-kappaB Activator T-leukemia cells [60] 
E2A (E47 & E12) Activator B-cells [61] 
SREBP-1A/2 Activator Liver carcinoma [62] 
SALL2 Activator ovarian carcinoma [63] 
KLF4 Activator Mesenchymal stem cell [64] 
RUNX1 Activator Mesenchymal stem cell [64] 
MyoD Activator Myoblasts [59] 
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MITF  Activator Melanoma  [65] 
CREB Activator Keratinocytes and myoblasts [59] 
STAT (1/3) 
proteins 
Activator Breast cancer [66] 
Sp1/3 Activator Colon adenocarcinoma [67] 
Smad3/4 Activator Liver carcinoma (hepatocytes) [68] 
TBX1 Repressor DiGeorge syndrome [69] 
Bmi1 Repressor Neural progenitor cells [70] 
c-Myc Repressor Normal kidney fibroblast [71] 
AP-1 (c-Jun) Repressor Liver cancer [72] 
CITED2 Repressor Lung cancer [73] 
PRMT6 Repressor Fibroblasts  [74] 
CDC6 Repressor Intestinal epithelium cells [75] 
CBX7 Repressor Lung fibroblasts [76] 
SKP2 Repressor Transformed cells  [77] 
FOXM1 Repressor Liver (hepatocytes) [78] 
ZNF76 Repressor Osteosarcoma  [79] 
Chk1 Repressor Colorectal cancer  [80] 
Brn-3a Repressor Neuronal cells [81] 
FBI-1 Repressor Osteosarcoma  [82] 
CUT Repressor Fibroblasts  [83] 
DNMT1 Repressor Breast cancer  [84] 
ID (1/2/3) family Repressor Gastric epithelial cells [85] 
TBX2/3 Repressor Breast cancer [86] 
Wnt1/4 Repressor Liver cancer [87] 
1.3.2 Post-transcriptional regulation of p21  
miRNAs, a group of noncoding RNAs of ~22 nucleotides long, regulate gene 
expression at the post-transcriptional level [88]. miRNAs can bind to the 5’- and/or 3’-
untranslated region (UTRs) of a mRNA molecule and control the translational efficiency and 
stability of the target mRNA [89]. Several reports have previously demonstrated that miR-17, 
miR-20a, miR-20b, miR-93, miR-106a, and miR-106b can down-regulate the p21 expression 
through binding to the p21 3′-UTR mRNA. As a result, overexpression of these miRNAs has 
been found to increase cell proliferation and increase G1/S transition [90-94]. In contrast to 
these results, it has also been found that the let-7a miRNA can indirectly increase p21 protein 
expression by targeting NIRF (Np95 ICBP90 ring finger), but exactly how this occurs is not 
understood [95]. 
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1.3.3 Post-translational regulation of p21 
p21 can be phosphorylated by Cyclin E-CDK2 at Ser-130, which leads to decreased 
p21 stability via the ubiquitin-dependent degradation. In contrast, JNK and p38 phosphorylate 
p21 at Ser-130 and increase p21 stability and translation [96, 97].  
 
1.3.4 Epigenetic regulation of p21 
Epigenetic alterations include both DNA modifications (methylation of CpG islands), 
and alterations in DNA packaging (chromatin remodeling) by post-translational histone 
modifications. Methylation of CpG islands in promoter regions cause transcription repression 
and gene silencing [98], whereas histone deacetylation leads to transcriptionally inactivation 
of chromatin [99]. DNA hypermethylation of the p21 gene has been reported in p21-silenced 
cells in some cancer types i.e. in lung cancer [100]. In addition, CpG methylation across exon 
1/intron 1 of the rat p21 gene has also been reported, which suggests defective p21 activation 
[100].  
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1.4 Aims of the study 
The overall aim of the study was to evaluate expression and regulation of p21 in 
melanoma, with the benefit for potential therapeutic applications in the future.   
The specific aims of the study can be summarized as follows: 
 Measure the expression of p21 at mRNA and protein levels in a melanoma cell panel 
and compare levels against disease stage and mutational status. 
 Measure mRNA levels of a number of genes previously reported to regulate p21 
expression and compare with p21 expression levels. 
 Investigate and study the effect of MAPK-, PI3K- and cAMP-pathway modulation and 
their effects upon p21 expression after treatments.  
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SECTION II: MATERIALS AND METHODS 
2.1 Reagents and materials 
 
Table 2.1.  Reagents and materials used in the study. 
Product Company  
2-Mercaptoethanol SIGMA-ALDRICH (St Louis, 
USA) 
Absolute alcohol Prima Kemetyl (Norway) 
Albumin from bovine serum (BSA) SIGMA-ALDRICH (St Louis, 
USA) 
ART TIPS  Thermo Scientific (USA) 
Aprotinin 2.0 mg/ml SIGMA-ALDRICH (St Louis, 
USA) 
BD Matrigel
TM 
Basement Membrane Matrix BD Biosciences, VWR 
BI-D1870 (RSK inhibitor) Merck millipore (UK) 
Bovine plasma gamma globulin (Protein standard 1) BIO-RAD Laboratorios (USA) 
Cell flasks 75 cm
2 
and 175 cm
2
  with filter cap NUNC
TM
, Thermo Scientific 
(Denmark) 
Cell scraper S TPP
®
, Techno Plastic Products 
AG (Switzerland) 
Countess
TM 
cell counting chamber slides Invitrogen by Life 
Technologies (UK) 
Dimethyl sulfoxide (DMSO) SIGMA-ALDRICH (St Louis, 
USA) 
Fetal bovine serum (FBS) PAA, Fisher Scientific (USA) 
GenElute
™
 Mammalian Total RNA Miniprep Kit SIGMA-ALDRICH (St Louis, 
USA) 
H-89 (PKA inhibitor) Cell Signaling (Canada) 
Hard-Shell PCR plates, 96 well Full C/C BIO-RAD Laboratories (USA) 
iBlot
®
 Gel Transfer Stacks, Nitrocellulose, Regular Novex
®
 by life technologies 
(Norway) 
IQ SYBR
®
 Green Supermix Quanta Bioscience (USA) 
Isopropanol prima ARCUS KJEMI AS (Norway) 
Leupeptin 2.0 mg/ml SIGMA-ALDRICH (St Louis, 
USA) 
L-Glutamine GibcoBRL (UK) 
Lysis solution for total RNA kit SIGMA-ALDRICH (St Louis, 
USA) 
MOPS SDS running Buffer (20X) Invitrogen Ltd, NuPAGE (UK) 
NaAzid (NaN3) 25%  BIO-RAD Laboratories (USA)
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Non-fat dry milk TINE meierier (Norway) 
Nunclon
®
 ∆ Surface, 6 well plate flat bottom NUNCLON, Thermo Scientific 
(Denmark) 
NuPAGE
®
 4-12 % Bis-Tris Midi Gel, 1.0 mm x20 
well 
Novex by life technologies 
(Norway) 
NuPAGE
®
 LDS (lithium dodecyl sulphate) sample 
buffer (4X) 
BIO-RAD Laboratories (USA) 
NuPAGE
®
 Sample Reducing Agent (10X) BIO-RAD Laboratories (USA) 
Optical Tape BIO-RAD Laboratories (USA) 
PCR tubes (thin wall) Axygen scientific, VWR 
(USA) 
Pepstatin A 2.0 mg/ml SIGMA-ALDRICH (St Louis, 
USA) 
Phenylmethylsulfonyl fluoride (PMSF) SIGMA-ALDRICH (St Louis, 
USA) 
Phosphate Buffered Saline (PBS), 0.0067 M (PO) Lonza, Biowhittaker (Belgium) 
Phosphate Inhibitor Cocktail Tablets (Phos STOP) Roche (Germany) 
Plexxikon 4032 (BRAFV600E inhibitor) Merck millipore (UK) 
Polyclonal Goat, Anti-Rabbit 
Immunoglobulins/HRP 
Dako (Denmark) 
Polyclonal Rabbit, Anti-Mouse 
Immunoglobulins/HRP 
Dako (Denmark) 
Protein Assay Dye Reagent BIO-RAD Laboratories (USA) 
qScript
™
 cDNA Synthesis Kit Quanta, BIOSCIENCES (USA) 
Real time PCR primers (human species specific 
(L+R)) (see Appendix B)  
IDT
® 
(Norway) 
RPMI 1640 without L-Glutamine Lonza, Biowhittaker (Belgium) 
SafeSeal Micro Tubes SARSTEDT (Germany) 
SeeBlue
®
 Plus2 Prestained Standard Novex by life technologies 
(Norway) 
Sodium chloride Merck (Germany) 
Super Signal West Dura Extended Duration 
Substrate 
Thermo Scientific (USA) 
Tris-HCL 1 M, PH 7.5 Gibco by life technologies 
(Norway) 
TRYPSIN EDTA, 200 mg/l Versene (EDTA) Lonza, Biowhittaker (Belgium) 
Tween 20 Merck (Germany) 
UO126 (MEK1/2 inhibitor) Cell Signaling (Canada) 
Venor
TM
Gem Classic Mycoplasma detection kit  Minerva biolabs ( Germany) 
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Cell lines 
Human melanoma cell lines were obtained from the American Type Culture 
Collection (ATCC), the Coriell Institute (the Wistar collection) and the Norwegian Radium 
Hospital, see table 2.2. 
 
Table 2.2.  Melanoma cell lines used in the study. 
Cell lines Source Melanoma site Melanoma stage 
WM35 Coriell Institute (Wistar 
collection) 
Scalp/neck area Radial Growth phase 
WM1366 Coriell Institute (Wistar 
collection) 
- Vertical Growth 
Phase 
WM1341B Coriell Institute (Wistar 
collection) 
Skin Vertical Growth 
Phase 
WM983A Coriell Institute (Wistar 
collection) 
Abdomen Vertical Growth 
Phase 
WM115 Coriell Institute (Wistar 
collection) 
- Vertical Growth 
Phase 
FEMX-I Norwegian Radium Hospital 
(established in house) 
Lymph node Metastatic 
FEMX-V Norwegian Radium Hospital 
(established in house) 
Lymph node Metastatic 
LOX Norwegian Radium Hospital 
(established in house) 
Lymph node Metastatic 
WM852 Coriell Institute (Wistar 
collection) 
Skin Metastatic 
WM9 Coriell Institute (Wistar 
collection) 
Left axillary lymph 
node 
Metastatic 
WM239A Coriell Institute (Wistar 
collection) 
Right groin lymph 
node 
Metastatic 
WM45.1 Coriell Institute (Wistar 
collection) 
- Metastatic 
WM266-4 Coriell Institute (Wistar 
collection) 
Right thigh skin Metastatic 
A375 American Type Culture 
Collection (ATCC) 
Skin Metastatic 
MEWO American Type Culture 
Collection (ATCC) 
Lymph node Metastatic 
SKMEL28 American Type Culture 
Collection (ATCC) 
Skin Metastatic 
WM1382 Coriell Institute (Wistar 
collection) 
Axillary lymph node Metastatic 
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2.2 Cell culture 
By using in vitro human cell cultures we can study cells that grow outside their natural 
environment under controlled conditions. This is a valuable tool for cancer research, 
permitting experiments on biological material in a simplified system but it also has some 
limitations for scientists working with cultured cells such as: cell line cross-contamination, 
nutrient depletion in the growth media, changes in pH of the growth media, accumulation of 
apoptotic/necrotic (dead) cells and etc. 
 
2.2.1 Cell storage and retrieval of cells 
All cell lines were stored in liquid nitrogen tanks (-180°C) to preserve them over a 
longer period of time, when not in use. 
The procedure was as follows: 
The cells were frozen in complete growth medium supplemented in FBS 20% and 
Dimethyl sulphoxide (DMSO) (SIGMA-ALDRICH) 10% (details in table A2, Appendix A). 
DMSO is a cryoprotective agent that lowers the freezing point, allowing a slow freezing, and 
thus prevents crystal formation which may harm the cells. The cells were frozen gradually, 
first in -80°C over night, before they were transferred to a liquid nitrogen tank for long term 
storage. When retrieved, the cells were thawed and resuspended in preheated complete growth 
medium (RPMI1640 medium supplemented with 10% fetal bovine serum (FBS) and 2mM L-
glutamine 1%) as quickly as possible. The following day the medium was replaced to remove 
unattached cells and DMSO residues. 
 
2.2.2 Culturing conditions 
The cells were transferred from liquid nitrogen tanks to a water bath at 37C (water 
BATH SWBD, Stuart Scientific). Once liquid, cells were added to cell culture flasks (175 cm
2
 
with a filter cap NUNC
TM
, Thermo Scientific) containing 30 ml of complete growth medium 
(details in table A1, Appendix A). Next, cell culture flasks were kept at 37C in a humidified 
5 % CO2 incubator (HERA cell, VWR), hereafter referred to as normal growth conditions. A 
correct CO2 level is necessary to provide a buffering system for maintaining optimal pH 
conditions in the medium. The humidity is needed to prevent medium evaporation.  
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After 24 hours, the medium was replaced with fresh medium to remove residual 
DMSO from the freeze medium. The cells were typically grown for 2 weeks before used in 
experiments and they were detached and splitted each third or fourth day by using 1 ml 
trypsin with EDTA (TRYPSIN EDTA, 200 mg/l Versene (EDTA) Lonza, Biowhittaker). 
Cells were typically splitted in ratios between 1:3 to 1:10, depending on the growth rates of 
the different cell lines used. Cell detachment was confirmed visually and by a microscope 
(LEICA DMIL, Leica Microsystems TYPE 090-135.00). The cells were then resuspended in 
complete growth medium preheated to 37°C for further experiments (see section 2.2.4 for 
seeding out cells for treatment and experimental setup). 
 
2.2.3 Quality control 
The cells were always handled using sterile techniques to prevent contaminations like 
bacteria, yeast or fungus. Such contaminations can affect the cells and thus question the 
reliability of the experiments. The cells were inspected for bacterial infections and changes in 
morphology on a daily basis using a light microscope, and routinely tested for Mycoplasma 
infection (VenorGem Classic Mycoplasma detection kit) by laboratory staff. All the cell lines 
used in the study consistently tested negative for mycoplasma infection. 
 
2.2.4 Seeding out cells for treatment and experimental setup 
For the initial screening of p21 related genes, 17 melanoma cell lines were seeded out 
and grown in T175 culture flasks. As the size of the cells and their growth rates differed 
among cell lines we chose to use cell confluence as our standard when seeding out cells.  
The procedure was as follows: 
 
Kinase inhibitor studies: 
A375 and SKMEL28 cells were seeded out and  grown to 60-80% confluence in 6-
well plates (Nunclon® ∆ Surface, plate flat bottom, Thermo Scientific) containing 3ml 
complete growth medium (see table A1, Appendix A). Cells were treated as shown in figure 
2.3 by replacing the culture medium with medium containing 10µM of the kinase inhibitors; 
Plexxikon (BRAF
V600E
 inhibitor), UO126 (MEK1/2 inhibitor), H-89 (PKA inhibitor), BI-
D1870 (RSK inhibitor), or combinations of 10µM of each of the respective inhibitors. The 
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cells were then incubated for 24 or 72 hours, followed by isolation of total RNA and/or 
protein. All 6-well plates contained a well with untreated control cells. Three independent 
biological experiments were used. Morphological changes caused by treatment with the 
inhibitors were captured using a Zeiss inverted microscope (ZEISS, Axiovert 200M, 
Germany) connected to an AxioCam CCD camera, and the images processed with the 
AxioVision software (see figure C1, Appendix C). A brief description of the inhibitors used in 
the experiment follows: 
Vemurafenib/PLX4032 (Merck Millipore) is a highly selective inhibitor of BRAF 
kinase activity which targets the BRAF
V600E 
mutation. PLX4032 was dissolved in DMSO to a 
concentration of 20 mM, aliquoted and stored at -20°C.  
UO126/MEK 1/2 Inhibitor (Cell Signaling) is a highly selective inhibitor of MEK 1 
and MEK 2. MEK 1 and MEK 2, also called MAPK or Erk kinases, are dual-specificity 
protein kinases that function in a mitogen activated protein kinase cascade controlling cell 
growth and differentiation. UO126 was dissolved in DMSO to a concentration of 10mM, 
aliquoted and stored at -20°C.  
H-89/PKA inhibitor (Cell Signaling) is a potent selective inhibitor of cAMP 
dependent protein kinase (PKA). H-89 was dissolved in DMSO to a concentration of 20mM 
aliquoted and stored at -20°C.   
BI-D1870/RSK inhibitor (Merck Millipore) is a potent and specific inhibitor of the 
p90 ribosomal S6 kinase (RSK) isoforms in vitro and in vivo, which inhibits RSK1, RSK2, 
RSK3 and RSK4 in vitro. BI-D1870 was dissolved in DMSO to a concentration of 10mM, 
aliquoted and stored at -20°C.  
 
Figure 2.3. Overview of the kinase inhibitor experimental setup in 6-well plates. 
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2.3 RNA analysis 
2.3.1 Harvesting RNA  
Cells were harvested for RNA by discarding the medium followed by a washing step 
with ice cold PBS before adding lysis solution (SIGMA-ALDRICH) containing 1% 2-
Mercapto ethanol (SIGMA-ALDRICH). Cells were then lysed with 650 µl lysis buffer for 2-3 
minutes at room temperature and the lysis suspension containing lysed cells were then added 
to eppendorf tubes (SafeSeal Micro Tubes, SARSTEDT). Cell tubes were stored at - 80C 
until RNA isolation. 
 
2.3.2 RNA isolation 
Total RNA was extracted from cells using the GenElute
™
 Mammalian Total RNA 
Miniprep Kit (SIGMA-ALDRICH) according to the manufacturer’s instructions. 
The procedure was as follows: 
 Transfer lysate to the blue filtration column and spin for 2 minutes at 14,000 × g. 
 Add equal volume of 70% ethanol to filtrate (650 µl) and mix thoroughly. 
 Transfer up to 700 µl lysate/ethanol mixture to clear binding column and spin for 15 
seconds at 14,000 × g. 
 Discard flow-through and repeat it for the rest of the solution. 
 Add 500 µl Wash Solution 1 to the column and spin for 15 seconds at 14,000 × g. 
 Transfer the column to a new collection tube. 
 Add 500 µl Wash Solution 2 to the column and spin for 15 seconds at 14,000 × g. 
Discard the Wash Solution. 
 Add second 500 µl Wash Solution 2 to the column and spin for 2 minutes at 14,000 × 
g to remove ethanol.  
 Discard the remained solution and spin for 15 seconds. 
 Transfer the column to a new collection tube. 
 Add 50 µl of elution solution to the column and spin for 1 minute at 14,000 × g. Store 
the RNA solution at -80°C. 
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2.3.3 Measuring RNA concentration 
The RNA concentration and purity were measured using a NanoDrop 2000 UV-VIS 
spectrophotometer (Thermo Scientific), which measures absorbance in small sample volumes. 
Absorbance was measured at the wavelengths of 260 nm, 280 nm and 230 nm. The absorption 
maximum of RNA is at 260 nm. These absorbance measurements provide data for calculating 
concentration and the ratios A260/280 and A260/230 give information about the purity of the RNA. 
The ratios were measured for each sample prior to using the RNA for further analysis. 
The absorbance ratio of A260/A280 is an important indicator of RNA purity and should 
be close to 2 for optimal purity. A lower ratio may indicate presence of contaminants like 
proteins and phenol, which absorb near 280 nm. The RNA samples with A260/280 ratio above 
1.8 were considered to have acceptable purity. The A260/230 ratio is used as a secondary 
measure of nucleic acid purity. Expected 260/230 values are commonly in the range of 2.0-
2.2. If the ratio is lower, it may indicate the presence of contaminants like guanidine 
thiocyanate and phenol which absorb at 230 nm. 
 
2.3.4 Isopropanol precipitation of RNA 
To increase the quality of the RNA samples that did not meet the criteria mentioned above, 
they were purified by isopropanol precipitation. 
The procedure was as follows: 
 Add equal volume of isopropanol and 0.1 volume of 3M sodium acetate PH 5.2 
to the RNA samples. 
 Precipitate over night at -20C. 
 Centrifuge at 14,000 × g for 40 minutes (4C). 
 Discard the supernatant carefully. 
 Wash the pellet with 100 l 75 % ethanol to remove impurities. 
 Centrifuge at 14,000 × g for 15 minutes. 
 Remove the ethanol and dry the RNA pellet by keeping the lid open for a few 
minutes. 
 Resuspend the pellet in 50 µl elution buffer and store at -80°C for further use. 
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2.3.5 cDNA synthesis (reverse transcriptase PCR) 
Complementary DNA (cDNA) was synthesized from total RNA using qScript
™
cDNA 
Synthesis Kit (Quanta, BIOSCIENCES). Reverse transcriptase is a DNA polymerase which 
synthesizes a double stranded DNA from a single stranded RNA template. Primers hybridize 
to the mRNA and allow the reverse transcriptase to synthesize cDNA from the mRNA present 
in the sample. 
The procedure was as follows:  
The cDNA synthesis reaction containing 1 g total RNA, 4.0 l qScript Reaction Mix (5x) 
(containing 5x concentrated solution of optimized buffer, magnesium, Oligo (dT), random 
primers, and dNTPs), 1.0 l qScript Reverse Transcriptase (50x) and nuclease free water were 
added to give a total reaction volume per sample of 20l. The cDNA synthesis was carried 
out in a GeneAmpPCR System 9700 thermal cycler (Applied Bioscience, USA). It was 
assumed that the conversion from RNA to cDNA had an efficiency of 100%. To obtain a 
concentration of 10ng/l, the cDNA was diluted to 100l in nuclease free water. Diluted 
cDNA was stored at -20°C. The cDNA temperature cycling program is shown in table 2.4. 
 
Table 2.4. Temperature cycle program for the cDNA synthesis. 
Temperature Time Function 
22 C 5 min Stabilizing samples 
42 C 30 min cDNA synthesis 
85 C 5 min Deactivation of enzyme 
6 C  Hold 
 
2.3.6 Gene panel  
 A list of 18 genes associated with p21 regulation was generated based on the 
literature studies, and is shown in table 2.5.  
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Table 2.5. List of p21 associated genes and their function. 
Gene Associated with 
CBX7 Cell-cycle control 
CDC6 Cell-cycle regulation 
CEBPA 
(C/EBPalpha) 
Interacting with CDK2 and CDK4 and causing growth arrest 
CITED2 p53-dependent apoptosis 
c-Myc Cell-cycle progression, apoptosis and cellular transformation 
ELK4 Ras-Raf-MAPK signaling cascade 
EP300 Cell proliferation and differentiation 
ID2/3 Cell growth, senescence and differentiation 
MITF Differentiation, development of melanocytes retinal pigment 
epithelium and pigmentation 
PRMT6 Transcriptional repression 
SALL2 p53-independent regulation of p21
 
SP1/3 Cell differentiation, cell growth and apoptosis 
TBX2/3 Tumorigenesis, cell proliferation, developmental processes and 
senescence 
TFAP2A (AP-
2alpha) 
Transcriptional activation/repression 
TFAP2C (AP-
2gamma) 
Cell differentiation and developmental processes 
 
2.3.7 Quantitative polymerase chain reaction (qPCR) 
Quantitative PCR is a method that allows quantification of gene expression based on 
mRNA levels. RNA is isolated from cells, cDNA is made by reverse transcription and real 
time PCR is run to detect the expression of genes of interest. The iQ SYBR Green Supermix 
kit (Quanta Bioscience) was utilized for monitoring both the generation of PCR products 
during amplification in real time and the denaturation of PCR products in the melting curve 
analysis.  
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The procedure was as follows:  
A master mix for each primer pair was prepared in a clean template free pre-PCR hood 
to prevent contamination. The PCR reaction contained 30 µl SYBR Green SuperMix (Quanta 
Bioscience), 1.6 µl of forward primer (10 pmol/µl), 1.6 µl of reverse primers (10 pmol/µl), 
and 16.4 µl PCR-graded water. For each sample, 50 µl of the master mix was added to 10 µl 
cDNA (10ng/µl) and mixed by vortexing. 25 µl of each sample was run in duplicates in a 96-
well Hard-Shell PCR plate. In addition, no template controls (blanks) were included for each 
primer pair (a reaction mix without cDNA template) as quality control for template 
contamination of the master mix. The qRT-PCR amplification was performed using the 
iCycler PCR machine (BIO-RAD) and the temperature cycling program is shown in table 2.6. 
 
Table 2.6. qRT-PCR temperature cycling. 
Step # Temperature Hold time Cycles Function 
1 95C 3 minutes 1 Initial 
denaturation 
2 
 
95°C 
60C 
10 
seconds 
35 
seconds 
42 Denaturation, 
annealing and 
extension 
3 95C 20 
seconds 
1 Denaturation 
4 55°-95C 
(in 0.5C increments) 
10 
seconds 
1  
Melt curve 
 
5 6C   Hold 
 
The initial denaturation of cDNA and activation of the DNA polymerase were 
performed in step 1, followed by 42 cycles of denaturing, annealing and extension in step 2. 
Melting curves were generated in step 4 by increasing the temperature in increments of 0.5°C. 
Fluorescent signal was monitored in step 2 (amplification reaction) and in step 4 (the melt 
curve analysis). In the final step the samples were cooled down to 6°C. The data was analyzed 
using the iCycler software. 
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qPCR primer design and efficiency 
 A successful real-time PCR reaction requires efficient and specific 
amplification of the product. Quantitative real time PCR primers specific for the 18 genes in 
table 2.5 were designed using the Roch Universal Probe Library (UPL) software. The 
specificity of each primer pair was assessed by gel-electrophoresis of the PCR products 
generated during amplification. This was done by running 5µl aliquots of PCR product from 
each assay mixed with 1.2 µl loading dye on a TBE gel. The molecular weight of the PCR 
products were estimated with the aid of a molecular weight standard and compared to the 
theoretical weight of the respective PCR products. The primers were considered specific only 
if a single PCR product with the correct molecular weight was detected on the gel. Next, in 
order for the primers to be considered in a quantitative real-time PCR assay, the efficiency of 
the primers had to be assessed. Small differences in amplification efficiency between sample 
and reference genes can generate false expression ratios, ultimately leading to over-/under 
estimation of the initial mRNA amount. Thus, primer efficiency tests were performed for all 
primers using cDNA from the MEWO cell line as template. A primer efficiency of 92-105% 
was considered satisfactory. The qPCR primer sequences and amplification efficiency are 
shown in table B1, figure B2 and table B3, Appendix B.  
 
Relative quantification and melting curve analysis 
SYBR green is a double-stranded DNA binding dye, which unbound exhibits minimal 
fluorescent. However, in PCR reactions its signal increases proportional to the amount of 
double stranded nucleic acids generated during amplification. The Ct-values of test samples 
were compared to those of control samples, yielding the fold difference of target nucleic acids 
in the test sample relative to control sample. The Ct (cycle threshold)-value is defined as the 
number of cycles required for the fluorescence signal in the PCR reaction to reach this 
threshold. The expression of housekeeping genes were used to ensure that the target quantities 
were compared from equivalent amount of sample. In the present study TATA-binding 
protein (TBP) and large ribosomal protein (RPLPO) were selected as appropriate 
housekeeping genes. The melting curve analysis was primary used to monitor the uniformity 
of the amplified PCR products. As the temperature is raised, the PCR products incorporated 
with the SYBR green dye begins to dissociate, leading to decreased fluorescent signal. Figure 
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2.7 shows the negative differentiated fluorescent signal as a function of temperature plotted 
against the temperature. The peaks observed in the diagram represent the melting temperature 
(Tm) of a product generated in the assay. 
 
Figure 2.7. Temperature plot displaying melting peaks of an amplified PCR product. 
 
2.4 Protein analysis 
2.4.1 Harvesting protein 
The procedure was as follows: 
Culture medium was discarded from 6-well plates and cells were washed with ice cold 
PBS to remove serum residual. Cells were then detached in ice cold PBS using a cell scraper 
(cell scraper S (TPP
®
, Techno Plastic Products AG) and transferred to a 15 ml centrifuge 
tube. The tubes were then centrifuged at 4°C by using a PICO 21 Centrifuge (THERMO 
SCIENTIFIC), at 3000 g for 5 minutes. The supernatant was discarded and the cells washed 
in 1 ml of cold PBS and transferred to eppendorf tubes (SafeSeal Micro Tubes, SARSTEDT) 
on ice. After a new centrifugation at 4°C by using an eppendorf Centrifuge 5810 R at 3000 g 
for 5 minutes, the supernatant was discarded and cell pellets were immediately frozen at -
80°C until protein isolation.  
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2.4.2 Protein isolation 
To extract proteins from cells, the cells need to be disrupted without altering the 
proteins of interest.  
 The procedure was as follows: 
Cell pellets stored at -80C were immediately placed on ice and lysis buffer containing 
a cocktail of protease inhibitors and phosSTOP (Phosphate Inhibitor Cocktail Tablets, Roche) 
(see table 2.8 for details) was added to the samples. A mild non-ionic detergent solubilizes the 
cell membranes and lyses the cells, liberating the cell contents. Protease inhibitors were added 
to prevent proteases from degrading the proteins and phosphatase inhibitor was added to 
preserve phosphorylation status of the phosphorylated proteins. The amount of lysis buffer 
used depended upon the size of the pellets, ranging from 25 l to 500 l. The samples were 
then incubated on ice for 30 minutes and vortexed every tenth minute for at least 3 times to 
lyse the cells. Next, cell lysates were ultrasonicated at 4C in short bursts by dipping the 
probe in the tubes three times for 3 seconds to disrupt the cells by high-frequency sound 
waves (20-50 kHz) in order to ensure complete extraction of proteins. After sonication, the 
samples were centrifuged at 14000 g for 15 minutes (4C) before the supernatants were 
transferred to new eppendorf tubes and stored at -80 C. 
 
Table 2.8. Constituents of stock lysis buffer and lysis buffer with inhibitors. 
Lysis Buffer (50 ml): Lysis Buffer with inhibitors: 
1.5 ml 5M NaCl 900 l lysis buffer 
2.5 ml 1M Tris-HCl0 ml 0.5 M 
Tris PH 7.5 
10 l 2 mM aprotinin 
50 l Nonidet P40 (NP-40) 10 l 2 mM leupeptin 
45 ml ddH2oDouble distilled 
H2O up to 50 ml 
10 l 2 mM pepstatin A 
 10 l 2 mM PMSF 
 100 l PhosSTOP 10X (1 
tablet dissolved in 1 ml ddH2o) 
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2.4.3 Measuring protein concentration 
Protein concentrations were measured using BIO-RAD Protein Assay (Bradford 
assay) which utilizes a color reaction and can be quantified by the WALLAC 1420 
MULTILABEL COUNTER (WALLAC VICTOR
2
, Finland) at 595 nm. The Bio-Rad 
solution contains the dye Coomassie brilliant blue G-250, which will change color when it is 
in contact with proteins. By using a dilution curve of a reference protein with a known 
concentration, the concentration of the protein in the sample can be quantified. The dye binds 
primarily to Arginine side chains, and slightly to other basic and aromatic residues. The 
amino acid composition of the protein therefore influences the level of dye binding. The 
protein lysate was assumed to have similar overall amino acid composition as the reference 
protein bovine gamma globulin (BGG). 
 The procedure was as follows: 
 Bio-Rad Protein Assay Dye Reagent Concentrate was diluted 1:5 in water. 
 A dilution series of 0, 1, 2, 3, 4 and 5 µg of the reference protein was added in 3 
parallels in a 96-well plate and ddH2O was added to obtain a total volume of 10 µl 
(see table B4, Appendix B). 
 1 µl of each lysate sample was pipetted on the plate in 3 parallels and ddH2O was 
added to obtain a total volume of 10 µl. 
 100 µl of Bio-Rad solution was added to each well. 
 After a minimum of 5 minutes of incubation in room temperature, the absorbance at 
595 nm was measured by a WALLAC VICTOR
2
 plate reader. 
 The protein concentration of the samples were calculated based on the standard curve 
that was generated by plotting the absorbance at 595nm against reference protein 
(bovine gamma globulin) concentration (1.37 mg/ml),  (see figure B5, Appendix B). 
 
2.4.4 LDS-PAGE (Lithium Dodecyl Sulphate Poly Acrylamide Gel 
Electrophoresis)  
Proteins are separated according to their size (molecular weight) by the use of an 
electric current in electrophoresis. The secondary structures of the proteins are denatured by 
heat and the anionic detergent LDS (lithium dodecyl sulphate) binds to hydrophobic groups 
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along the polypeptide, giving it a uniform negative charge. Proteins will then be distributed 
according to mass. Adding a reducing agent cleaves disulfide bonds and disrupts the tertiary 
and quaternary structure, and thus denatures the proteins further. The resulting denatured 
linearized protein with uniform mass/charge ratio makes it possible to separate the proteins 
based on size only, not influenced by native 3D structure and charge. Smaller proteins migrate 
faster than larger proteins, which are delayed in a porous matrix such as a polyacrylamide gel. 
 The procedure was as follows: 
 
Preparing samples 
Protein samples were prepared on ice as follows: 2.5 l NuPage sample buffer (LDS 
4X), 1 l NuPage reducing agent 10X and 20-30 g protein were mixed with de-ionized 
water to make a total volume of 10 l. The sample buffer (LDS) contains glycerol which 
increases the density of the samples and makes them sink into the wells. It also contains 
bromophenol blue which enables visualization and tracking of the sample migration through 
the gel. The samples were then heated to 70C for 10 minutes on a heat block to promote 
denaturation, followed by incubation on ice. Samples were then centrifuged to spin down all 
the liquid before application on the gel. 
 
Gel electrophoresis 
The gel system was assembled and filled with running buffer 3-(N-morpholino) 
propane sulfonic acid, 20mM (MOPS) which separates the proteins over a molecular weight 
ranging from 1-200 kDa. The gels used were NuPAGE Novex 4-12% Bis-Tris Midi Gel 1.0 
mm with 20 wells (Life technologies). The gels had an increasing density from 4-12% of 
polyacrylamide. Before samples were applied, the wells were rinsed with running buffer to 
remove possible unwanted gel material and bubbles. To be able to estimate the sizes and 
identify the proteins in gel, 2.5 l of the protein marker, Sea Blue Plus2 Pre-stained Standard 
was used on each gel in the first well, and in the remaining wells 10 l of each sample were 
applied. The electrophoresis was assembled in an XCell4 Surelock
TM
 Midi-Cell chamber on 
160 V for 1-1.5 hours. 
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2.4.5 Western blotting 
Western blotting is a widely used method for separation and detection of specific 
proteins. Proteins in the gel are transferred to a membrane and incubated with antibodies to 
detect the specific protein of interest.  
 
Blotting  
The procedure was as follows: 
After the running procedure was completed, proteins were transferred from the gel 
matrix to a nitrocellulose membrane using a dry blotting system (iBlot, Invitrogen). The gel 
was assembled on a nitrocellulose membrane in between a top and bottom stack (iBlot Gel 
Transfer Stacks Nitrocellulose). Using an iBlot Gel Transfer Device, the gel was blotted onto 
the nitrocellulose membrane by applying 23 V for 9 minutes. High field strength and current 
during blotting make the transfer of proteins efficient and fast. 
 
Blocking 
The procedure was as follows: 
To reduce non-specific binding of primary or secondary antibody to the membrane, the 
membrane is blocked by agents that occupy space that is not already occupied by proteins. 
Hence, each membrane was specifically blocked with a blocking solution usually 5% dry milk 
in 0.1% TBS-T (Appendix A, table A4) or 5% BSA in 0.1% TBS-T for at least 1 hour at 
37C. 
 
Primary antibodies 
 The procedure was as follows: 
Membranes were incubated with primary antibodies diluted in 5% dry milk in 0.1% 
TBS-T or 5% BSA in 0.1% TBS-T over night at 4°C with continuous gentle movement. The 
primary antibodies were used several times and conserved by adding 0.05% sodium azide 
(preservative) to prevent bacterial growth. All of the antibodies were purchased from Cell 
Signaling Technology (Canada) except the p53 antibody, which was purchased from Santa 
Cruz Biotechnology (USA). An overview of the conditions used for antibody specifications in 
this study is presented in table 2.9. 
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Table 2.9. Antibody conditions used for Western Blot. 
Primary Ab name Size 
(kDa) 
Blocking 
conditions  
Primary  
Ab dilution 
 
Secondary 
Ab dilution  
Buffer for Ab 
dilution 
Histone H3 17 5% dry milk 1:3000 1:8000 
(rabbit) 
5% Dry milk in 
TBS-T 
p21 Waf1/Cip1 21 5% BSA 1:1000 1:5000 
(rabbit)  
5% BSA in TBS-
T 
AKT 60 5% BSA 1:1000 1:5000 
(rabbit)  
5% BSA in TBS-
T 
p-AKT (Ser473) 
XP 
60 5% BSA 1:2000 1:6000 
(rabbit) 
5% BSA in TBS-
T 
ERK 1/2 
(Thr202/204) 
44/42 5% BSA 1:2000-
1:3000 
1:7000 
(rabbit) 
5% BSA in TBS-
T 
p-ERK 1/2 44/42 5% BSA 1:2000 1:7000 
(rabbit)  
5% BSA in TBS-
T 
CREB (48H2) 43 5% BSA 1:1000 1:5000 
(rabbit) 
5% BSA in TBS-
T 
p-CREB (Ser133) 
 
43 5% BSA 1:1000 
 
1:5000 
(rabbit) 
 
5% BSA in TBS-
T 
p-STAT1 (Ser727) 91 5% BSA 1:1000 1:5000 
(rabbit) 
5% BSA in TBS-
T 
p53 (FL393) 53 5% Dry milk 1:500 1:2000-
1:3000 
(rabbit) 
5% Dry milk in 
TBS-T 
MITF 50-75 5% BSA 1:1000 1:5000 
(rabbit) 
5% BSA in TBS-
T 
AMPK 62 5% BSA 1:1000 1:5000 
(rabbit) 
5% BSA in TBS-
T 
p-AMPK (Thr 
172) 
62 5% BSA 1:1000 1:5000 
(rabbit) 
5% BSA in TBS-
T 
 
Washing step 1 
 The procedure was as follows: 
The membranes were washed 3x for 10 minutes with wash buffer (TBS buffer 
containing 0.1% Tween 20 (Appendix A, table A4)).  
 
Secondary antibodies 
 The procedure was as follows: 
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Membranes were incubated with secondary antibody diluted with 5% dry milk in 0.1% 
TBS-T or 5% BSA in 0.1% TBS-T at room temperature for 1 hour using a shaker with gentle 
movement. See table 2.9 for secondary antibodies used in this study. 
 
Washing step 2 
 The procedure was as follows: 
The membranes were then washed 3x for 10 minutes with wash buffer (TBS buffer 
containing 0.1% Tween 20 (Appendix A, table A4)). 
 
Detection  
The protein of interest is detected by a primary antibody specific to the protein. This 
antibody is in turn detected by a secondary antibody, targeting the constant region of the 
primary antibody. The secondary antibodies carry a label, typically horseradish peroxidase 
(HRP), which by oxidizing a substrate emits a measurable signal proportional to the amount 
of target protein present (figure 2.10). Due to the specificity of immunodetection, it is possible 
to detect small amounts of a specific protein in a sample with many different proteins. 
Chemiluminescence occurs when a chemical reagent containing stored energy releases light. 
The reagent is normally stable and does not emit light, but can be converted into a light 
emitting product, for example after interaction with a specific enzyme.  
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Figure 2.10. Detection by antibodies. The protein of interest is bound by a specific primary 
antibody, which in turn is detected by a HRP-linked secondary antibody, which enables 
electrochemiluminescence (ECL) detection. Figure reproduced with permission from 
“Western blotting, Principle and Methods, 28-9998-97AA GE Healthcare Life Science” 
[101]. 
 The procedure was as follows: 
The proteins on the membranes were visualized using Super Signal West Dura 
Extended Duration Substrate reagent (Thermo Scientific). The HRP on the secondary 
antibodies oxidizes the added substrate in the presence of hydrogen peroxide, and 
chemiluminescence was detected by a light sensitive camera G: box iChem (Syngene, UK) 
with the associated GeneSnap version 7.12 software. Image analysis was carried out with 
GeneSnap version 7.12 and GeneTools. 
 
Loading control 
For each membrane, the amount of protein loaded in each well was controlled by 
detection of a housekeeping protein, which is supposed to be present at approximately equal 
amount in all cells. For this purpose, the housekeeping protein Histone H3 was used as the 
loading control.  
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SECTION III: RESULTS 
3.1. Characterization of melanoma cell lines 
In order to be able to compare p21 expression levels against the disease stage and the 
mutational background of each cell line used in the study, a table was made (see table 3.1). 
Information about the disease stage and the mutational background of each cell line was 
obtained from the literature, the Wistar Institute webpage (link: 
http://www.wistar.org/lab/meenhard-herlyn-dvm-dsc/page/melanoma-cell-lines-0) and the 
Coriell Institute webpage (link: 
http://ccr.coriell.org/Sections/Collections/WISTAR/CellLines.aspx?PgId=572&coll=WC). 
Cell line Stage BRAF H/N-Ras p53 
WM35 RGP V600E
 WT WT 
WM115 VGP V600D
 WT WT 
WM1341B VGP V600R
 WT WT 
WM1366 VGP WT 61L
 
Y220C
 
WM983A VGP V600E
 WT P278F
 
WM45.1 Metastatic V600E
 WT Y220C
 
WM239A Metastatic V600D
 WT WT 
WM266-4 Metastatic V600D
 WT WT 
WM852 Metastatic WT 61R
 
S241F
 
WM1382 Metastatic WT WT WT 
LOX Metastatic V600E
 WT WT 
FEMX-I Metastatic WT Mut
 WT 
FEMX-V Metastatic WT Mut
 WT 
SKMEL28 Metastatic V600E
 WT L145R
 
MEWO Metastatic WT NF1/Q1336
 
Q317/E258K
 
A375 Metastatic V600E
 WT WT 
WM9 Metastatic V600E
 WT WT 
 
Table 3.1. The table shows the disease stage and BRAF, H/N-Ras, and p53 mutations in our 
melanoma cell panel. RGP and VGP are short for Radial Growth Phase and Vertical Growth 
Phase, respectively. Mutated genes are shown with stars (*). Abbreviations: WT, wild-type; 
Hem Del, hemizygous deletion; Hom, homozygous; Het, heterozygous; Mut, mutant; R, 
arginine; Q, glutamine; E, glutamic acid; K, lysine; L, leucine; V, valine; Y, tyrosine; C, 
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cysteine; D, aspartic acid; T, threonine; A, alanine; S, serine; P, proline; F, phenylalanine: 
NF1 (gene), Nuclear factor I. 
 
3.2 p21 expression in melanoma cell lines 
3.2.1 Expression of p21 mRNA levels in the cell panel  
To investigate p21 mRNA expression levels in the melanoma cell panel we used the 
Real-Time RT-PCR method. Results showed variable amount of p21 mRNA in the cell panel. 
When we arranged the cell lines after the progression of the disease we found no obvious 
expression pattern (see figure 3.2). Highest level of p21 mRNA, compared to WM35 (control), 
was measured in the LOX cell line. However, high p21 mRNA expression levels were also 
detected in WM115, WM1341B, WM266.4, WM239A, and WM1382, compared to WM35. 
Cell lines such as WM983A, WM1366, FEMX-I, SKMEL28, MEWO, and WM45.1 
displayed low levels of p21 mRNA compared to WM35, while WM852, WM9, A375, and 
FEMX-V showed more or less comparable levels as WM35. Together, these data suggests 
that there is no general increase or decrease in p21 mRNA levels when comparing against the 
progression of the disease from RGP to VGP and metastatic stages in our melanoma cell line 
panel. 
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Figure 3.2. The graph shows p21 mRNA expression levels in our melanoma cell panel. Data 
is presented as LOG2 and cell lines were normalized to WM35 (a cell line from the RGP 
stage). Blue bars represent VGP cell lines, while grey bars represent metastatic cell lines. 
Error bars represent standard deviation (SD) from three biological parallels. 
 
3.2.2 Expression of p21 protein levels in the cell panel  
To investigate p21 protein expression levels in our melanoma cell line panel, we used 
the western blotting method. As for p21 mRNA expression levels, we did not see any 
correlation between the p21 protein levels and the various stages of the disease (RGP, VGP, 
and metastatic) (see figure 3.3). High levels of p21 protein levels were found in WM115, 
WM1341B, WM239A and WM1382. In cell lines such as LOX, WM266.4, WM9 and WM35, 
we detected low or very low levels of p21. No p21 protein was detected in WM983A, 
WM1366, FEMX-I and V, SKMEL28, MEWO, A375, WM45.1 and WM852.  
 
p21 protein levels in the melanoma cell lines 
 
 
 
 
 
Figure 3.3. Western blot shows p21 protein expression in our melanoma cell panel (cell lines 
are arranged after disease stage). Cell lines from the RGP and VGP stages are underlined. 
Histone H3 (H3) was used as a loading control. The western blot pictures shown are 
representative for one out of two parallels. 
 
3.2.3 Comparing p21 mRNA levels with p21 protein levels 
To investigate a potential role of microRNAs (miRNAs) in post-transcriptional 
regulation of p21, we compared p21 mRNA expression levels (figure 3.2) with the p21 
protein expression levels obtained from the western blotting (figure 3.3). Together, these 
results showed that there was a strong positive correlation between p21 mRNA levels and the 
respective protein levels for all the cell lines except LOX.  
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3.3 p53-dependent regulation of p21 expression  
3.3.1 Comparing p21 mRNA levels upon the p53 status  
According to the literature, p53 is a major transcriptional regulator of p21 expression. 
Here, we wanted to investigate the correlation between p21 mRNA expression and the p53 
status in our melanoma cell line panel. Our results showed that cell lines with mutated p53 
(WM1366, WM983A, WM45.1, WM852, SKMEL28 and MEWO) have in general much 
lower levels of p21 mRNA compared to WM35, which contain wild-type p53 (figure 3.4). 
Cell lines with wild-type p53 such as WM115, WM1341B, WM239A, WM266-4, WM1382, 
and LOX had higher p21 mRNA levels than WM35, while the p53 wild-type cell lines like 
FEMX-I and V, A375 and WM9 had comparable or lower levels. Together, these results 
showed that there is a good correlation between p21 mRNA expression levels and the p53 
status.  
 
Figure 3.4. The graph shows p21 mRNA expression levels in our melanoma cell panel. Data 
is presented as LOG2 and cell lines were normalized to WM35 (a cell line from the RGP 
stage). Green bars represent p53 wild-type cell lines, while red bars represent p53 mutated 
cell lines. Error bars represent standard deviation (SD) from three biological parallels. 
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3.3.2 Comparing p53 protein levels with p21 protein levels  
After studying the correlation between p21 mRNA levels and p53 status we were 
interested in comparing p21 protein levels with p53 protein levels. For this, we used the 
western blot procedure and our results are shown in figure 3.5. Interestingly, our results 
showed that melanoma cell lines which were mutated for p53 had much higher expression of 
p53 than wild-type p53 cell lines. None of the cell lines with mutated p53 had any detectable 
level of p21, which was in agreement with our Real-Time RT-RCR data. All the cell lines 
with high p21 protein levels had low or close to undetectable levels of p53 protein. 
 
p53 protein levels in the melanoma cell lines 
 
 
 
 
 
 
 
 
 
Figure 3.5. Western blot shows p21 and p53 protein expression in our melanoma cell panel 
(cell lines are arranged after disease stage). Cell lines from the RGP and VGP stages are 
underlined. Histone H3 (H3) was used as a loading control. The western blot pictures shown 
are representative for one out of two parallels. 
 
3.3.3 Comparing p21 protein levels upon the p53 status after treatment 
with inhibitors 
To further address the correlation between p21 and p53, we measured protein levels of 
p21 and p53 after inhibitor treatments (72 hours) in A375 (p53 wild-type) and SKMEL28 
(p53 mutated) respectively (figure 3.6). Our data showed that p21 protein levels decreased 
dramatically in the A375 cell line after single treatments like PLX4032 (BRAF
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UO126 (MEK1/2). A strong decrease in p21 protein levels was also detected after 
combination treatments such as: PLX+UO126, PLX+H-89 (PKA), and PLX+BI-D1870 
(RSK), while a minor decrease was observed in UO126+BI-D1870 and H-89+BI-D1870. Our 
results showed that p21 protein levels are comparable to p53 protein levels after inhibitor 
treatments. The exceptions were PLX+H-89 and H-89+BI-D1870 treatments, which showed 
an increase in p53 protein levels compared to untreated control. In treatments like H-89, BI-
D1870 and UO126+H-89 we observed an increase for both p21 and p53, compared to 
untreated control. For the SKMEL28 cell line we observed comparable changes in both p21 
and p53 protein levels as for A375 after the various treatments. Exceptions were the decline 
observed in both p21 and p53 protein levels after UO126+H-89 treatment, together with the 
decline in p53 protein levels in PLX+H-89 and H-89+BI-D1870. Together, the data showed 
that there is a strong positive correlation between p53 and p21 protein levels in both A375 and 
SKMEL28 after inhibitor treatments. 
 
p21 and p53 protein levels after treatments 
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Figure 3.6. Western blot showing protein expression of p21 and p53 after treatment (72 hours) 
with 10 µM of PLX4032, UO126, H-89, BI-D1870 and the combinations PLX+UO126, 
PLX+H-89, PLX+BI-D1870, UO126+H-89, UO126+BI-D1870 and H-89+BI-D1870 in a) 
A375 and b) SKMEL28. Histone H3 (H3) was used as a loading control. The western blot 
pictures shown are representative for one out of three parallels. 
 
3.4 p53-independent regulation of p21 expression 
3.4.1 mRNA expression of various p21 modulators  
Not only p53, but a large number of genes have been shown in previous articles to 
regulate p21 at the transcriptional level in different types of cancers and disorders (section 
1.3.1, table 1.8). Some of these regulators modulate p21 expression directly for instance, Sp1, 
c-Myc, MITF, AP-2 and TBX2, while others like p300 regulate p21 indirectly through 
MITF by CREB activation (see figure 3.7). 
 
Figure 3.7. An illustration over a proposed transcriptional network representing some 
potential p21 regulators in melanoma. 
 
A number of transcription factors can bind to the p21 promoter besides p53 (see figure 
1.7). In order to investigate potential p53-independent regulation of p21 transcription, we 
measured mRNA levels of the genes presented in figure 3.7, which previously have been 
reported to regulate p21 (see figure 3.8). 
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Figure 3.8. Real-time RT-PCR data showing mRNA expression levels of a) p21, b) c-Myc, c) 
AP-2α, d) TBX2, e) EP300, and f) SP1 in our melanoma cell panel. The blue bars represent 
cell lines from the vertical growth phase (VGP) and the grey bars represent cell lines that are 
in the metastatic stage. Results are presented as LOG2 and values from all cell lines are 
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normalized to WM35. Error bars represent standard deviation (SD) from three biological 
parallels. 
 
Our data showed that c-Myc is down-regulated in the whole melanoma cell panel in 
comparison to WM35 (used as control). AP-2 is down-regulated in WM1366, WM9, 
WM239A, A375, LOX and WM45.1, and up-regulated in the rest of the cell lines. 
Furthermore, the TBX2 gene is not expressed in WM1366 and LOX, and is down-regulated in 
FEMX-I, FEMX-V, SKMEL28, WM1382, A375 and WM45.1 and up-regulated in the rest of 
the cell lines. EP300 is up-regulated to some extent in WM115, WM983A, WM852 and 
WM45.1, while down-regulated moderately in WM1366, MEWO, A375 and LOX, and shows 
about unchanged expression levels in the rest of the cell lines. Finally, SP1 is down-regulated 
in WM1366 and SKMEL28, up-regulated in WM115, WM983A and WM852 and shows 
about unchanged expression in the rest of the cell lines. 
  When comparing the various mRNA expression levels of these transcription factors 
with the p21 mRNA levels throughout the cell panel we do not find any obvious correlation. 
As seen from figure 3.8, p21 mRNA is up-regulated in WM115, WM1341B, WM266-4, 
WM1382, WM239A and LOX and down-regulated in WM1366, WM983A, WM852, WM9, 
MEWO, FEMX-I, FEMX-V, SKMEL28, A375 and WM45.1. Data from other genes 
validated at the mRNA level are shown in Appendix C, Supplementary data, figure C2. 
 
3.4.2 Modulation of p21 regulators by chemical inhibitors 
To investigate the possible role of TBX2 and c-Myc as repressors, and AP-2 and 
MITF as possible activators of p21 transcription, we treated A375 and SKMEL28 with 
chemical inhibitors and analyzed their mRNA levels by real time RT-PCR (figure 3.9). Our 
results showed that the mRNA levels of p21 expression after treatment with PLX, UO126, H-
89 and BI-D1870 was in agreement with protein levels of p21 (figure 3.6) after 72 hours 
incubation in both cell lines; PLX and UO126 showed down-regulation of p21, while H-89 
and BI-D1870 showed a minor up-regulation. We then compared mRNA and protein 
expression levels of p21 with changes in TBX2, c-Myc, AP-2 and MITF mRNA levels. 
55 
 
 
 
 
 
Figure 3.9. Real-time RT-PCR data showing mRNA expression levels of p21, TBX2, AP-2, 
c-Myc and MITF in a) A375 and b) SKMEL28 after treatment with 10 µM PLX4032, UO126, 
H-89, and BI-D1870. Results are presented as LOG2 and values from all cell lines are 
normalized to untreated control. Error bars represent standard deviation (SD) from three 
biological parallels. 
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TBX2 mRNA levels were decreased in response to PLX, increased in response to 
UO126 and BI-D1870 and unchanged in response to H-89, in A375. This was in contrast to 
SKMEL28, where TBX2 was up-regulated in response to PLX, UO126 and BI-D1870, and 
unchanged in response to H-89. No correlation between TBX2 and p21 was found in A375, 
while a negative correlation was observed for SKMEL28. Furthermore, AP-2 mRNA 
expression levels were increased in response to PLX and UO126 in both cell lines, while less 
affected after H-89 and BI-D1870 treatment. The c-Myc transcription factor was down-
regulated in response to PLX and UO126, almost unchanged in response to H-89, and down-
regulated in response to BI-D1870 in both cell lines. Finally, we investigated MITF mRNA 
levels as a regulator of p21 mRNA production. MITF mRNA was down-regulated in response 
to all four treatments (approximately unchanged in response to UO126) in A375, which is in 
accordance with protein levels of MITF (figure 3.10 a). In SKMEL28, MITF mRNA was also 
down-regulated in response to all four treatments, however it was inconsistent with protein 
levels of MITF, indicating up-regulation in response to PLX and UO126 (figure 3.10 b). 
When we compared the MITF mRNA levels with the p21 mRNA levels we were not able to 
detect any correlation.  
3.5 Signal pathway modulation and p21 expression  
To investigate the effect of pathway modulation upon p21 expression we used small 
chemical inhibitors against the MAPK- and cAMP-pathways. We next analyzed 
phosphorylation status of a number of key genes in MAPK-, PI3K/AKT-, JAK/STAT- and 
cAMP- pathways that are believed to regulate melanoma development when deregulated. 
Figure 3.10 shows protein levels of ERK1/2 and AKT and their activated, phosphorylated 
forms p-ERK1/2 and p-AKT. In addition, the levels of MITF and p-STAT1, p21 and H3 
(loading control) were analyzed. Our data showed changes in pathway signaling in response 
to BRAF
V600E
, MEK1/2, PKA, and RSK inhibition as expected. When comparing changes in 
p21 protein levels after single treatments against the p-AKT/AKT we observed a strong 
positive correlation in the A375 cell line (Figure 3.10 a). A comparable strong positive 
correlation is detected when comparing p21 levels to ERK1/2 levels after single treatments. 
Surprisingly, the correlation was less obvious when comparing to p-ERK1/2, which showed 
strong down-regulation with both PLX and UO126 treatment. This was in contrast to the p21 
levels that showed strong down-regulation with PLX, and more moderate down-regulation 
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with UO126. The phosphorylation status of STAT1 was comparable to p-ERK1/2 after single 
treatments and MITF expression was more or less absent. When comparing p21 protein levels 
with the combination treatments for A375, we did not see any convincing correlation in either 
of the genes tested. For the SKMEL28 cell line, we did not observe any strong positive 
correlation between p21 protein levels and the genes investigated (figure 3.10 b). However, 
we observed a detectable negative correlation between p21 protein levels and MITF levels 
after single treatments. When we compared the pathway signaling after inhibitor treatment 
between the two cell lines SKMEL28 and A375, we observed substantial differences in 
phosphorylation status and protein amounts. Our results showed that the phosphorylation 
status of ERK1/2 was the only obvious common factor between the two cell lines in the tested 
genes.                                 
pathway modulation upon p21 expression 
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b) SKMEL28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. Western blot showing the expression of proteins involved in melanoma signal 
pathways after treatment with 10 µM PLX4032, UO126, H-89, BI-D1870 and combinations 
PLX+UO126, PLX+H-89, PLX+BI-D1870, UO126+H-89, UO126+BI-D1870 and H-89+BI-
D1870 in a) A375 and b) SKMEL28. Western blotting was performed to detect levels of ERK, 
AKT, their phosphorylated forms, in addition to MITF, p-STAT1, p21 and Histone H3 
(loading control). The western blot pictures are representative for three independent 
biological parallels. 
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SECTION IV: DISSCUSSION 
4.1 p21 expression in the melanoma cell panel 
The expression of p21 has previously been investigated both in vitro and in vivo in 
many different cancer cell types [22, 38, 102]. However, there are few studies that have 
investigated p21 expression in a large cell line panel, spanning the different stages of 
melanoma [25, 69, 95]. In this study, we aimed to investigate p21 expression at both the 
mRNA and protein level. In addition, we compared the expression levels of p21 against the 
stages of the disease and the mutational background of each cell line. From our Real-Time 
RT-PCR data we could not find any correlation between the mRNA values of p21 and the 
different stages of the disease. This result is in contrast to Mealandsmo et al. that measured 
low levels of p21 in benign nevi and high levels in metastatic melanoma [103]. The fact that 
our results are obtained from human melanoma cells in vitro; while Mealandsmo et al. 
investigated in vivo samples, may explain the discrepancy. Next, we compared the p21 
mRNA values obtained from our cell line panel with the mutational background of each cell 
line. Of note, only a few mutations for these cell lines have been described in the literature, 
including mutations in BRAF, RAS, and p53 (Table 3.1). Among the mutations in these genes, 
we detected a good correlation between the mutational status of p53 and p21 mRNA 
expression in our cell line panel. No correlation was found between p21 and BRAF, RAS 
status. This result is in agreement with previous studies, showing the regulatory role of p53 
upon p21 transcription [103-105]. All the cell lines containing the Y220C, L145R and 
Q317/E258K mutations had very low levels of p21 mRNA compared to the wild-type p53 cell 
line WM35 (used as control). A marked reduction of p21 mRNA was also measured in 
WM983A, which contains a P278F mutation in p53. Among the 6 cell lines in the cell panel 
with p53 mutation, only WM852 contained comparable levels of p21 as the wild-type p53 cell 
line WM35. The WM852 cell line has been described to have a S241F mutation in p53 [106]. 
Based on our results, it appears like the p53 mutation in WM852 does not affect p53-
dependent regulation of p21. Alternatively, other transcription factors in the p21 promoter 
region compensate for the loss of p53 by keeping p21 mRNA levels at comparable levels to 
the p53 wild-type cell line WM35. 
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 Of interest, the p53 wild-type cell line LOX contained 8-fold more p21 mRNA than 
WM35 and around 16-fold more than the FEMX-I cell line (also wild-type for p53). These 
results, suggest that there are large differences in p21 mRNA levels within the group of cell 
lines that are p53 wild-type. This may suggest that not only p53, but also p53-independent 
regulation of p21 transcription is occurring. Alternatively, p53 is more active in LOX than in 
the other cell lines.  
A few previous reports have shown that there is a good correlation between p21 
mRNA and protein expression levels [47, 103]. This is in agreement with our data, which 
show high expression of p21 protein in the cell lines that contain high levels of p21 mRNA 
(figure 3.2 and 3.3). The exception is LOX, showing very high levels of p21 mRNA, but close 
to no p21 protein (figure 3.2 and 3.3). This latter result implies possible post-transcriptional or 
post-translational regulation of p21 in LOX. Several miRNAs (miR-17, miR-20a, miR-20b, 
miR-93, miR-106a, and miR-106b) have been found to decrease p21 protein levels by binding 
to the 3`UTR of p21 [90-94]. Furthermore, post-translational regulation by GSK (Glycogen 
synthase kinase beta) may occur. GSK  have been found to phosphorylate Thr-57 at p21 and 
subsequently decreases protein stability [70]. Of note, cyclin E-CDK2 have also been found to 
decrease p21 stability by phosphorylation of p21 at Ser-130 [107]. The expression levels of 
p21 mRNA and protein can be modulated by several processes and in the next chapter we will 
discuss p53-dependent regulation of p21 transcription. 
 
4.2 p53-dependent transcriptional regulation of p21 
It has for a long time been well-known that p53 is a major regulator of p21 
transcription [71, 72, 108]. In this study we aimed to investigate whether this also was the 
case for our human melanoma cell lines. In our cell panel we had 6 cell lines that were p53 
mutant, while the remaining 11 cell lines contained p53 wild-type. As mentioned previously 
in this discussion under “p21 expression in the melanoma cell panel”, low or non-present 
levels of p21 mRNA and protein were detected in p53 mutated cell lines, respectively. These 
results imply that p53 status is important for p21 transcriptional regulation. The exception was 
WM852, which contained comparable p21 mRNA levels to the control p53 wild-type cell line 
WM35. The highest levels of p21 mRNA and protein was detected in WM115, WM1341B, 
WM239A, WM266-4 and WM1382, all of them p53 wild-type. These cell lines showed 
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higher p21 mRNA levels than other wild-type p53 cell lines such as WM35, FEMXI and V, 
A375, and WM9. A relevant question is then whether this difference in p21 mRNA levels is a 
consequence of p53-independent regulation or just an increase in p53 activity. Then 
investigating the amount of p53 protein between the two groups of p53 wild-type we were 
unable to detect any difference when inspecting the western blot pictures. This result implies 
that observed discrepancy in p21 mRNA levels is at least not due to the amount of p53 protein. 
Interestingly, the amount of p53 protein was much higher in p53 mutated vs. wild-type cell 
lines. This is consistent with other reports, showing high expression of p21 in the absence of 
p53 and on the contrary in in vitro and immunohistochemistry analysis [48, 109]. Our results 
support the suggestion that there also exist p53-independent regulation of p21 (which will be 
discussed in more details in the next chapter). The significance of p53-independent regulation 
of p21 in melanoma is nevertheless less understood. When using small molecular chemical 
inhibitors against the MAPK- and cAMP-pathway, we measured their effects upon p21 and 
p53 protein levels. In both the mutated p53 cell line (SKMEL28) and in the p53 wild-type cell 
line (A375), we observed a strong positive correlation between the two genes after single 
treatments with inhibitors. A good positive correlation was also detected after combination 
treatments in A375 and SKMEL28, however not as strong as for the single treatments. No 
differences between the cell lines (A375 and SKMEL28) were detected in response to 
chemical inhibitors after single treatments, while minor differences were observed after 
combination treatments. Interestingly, we observed down-regulation of both p53 and p21 after 
inhibiting BRAF
V600E
, in contrast to up-regulation of p53 and p21 when inhibiting RSK, both 
mediators in the same signal pathway (MAPK). At the present we do not have any 
explanation for these latter results and suggest that further evaluation by siRNA knock-down 
of the respective genes would be useful to disclose the different role of BRAF
V600E
 and RSK 
in the regulation of the p53/p21 pathway. 
In summary, p21 transcription has been found to be controlled by a vast number of 
different transcription factors; however, our results suggest a major role for p53 as a 
transcriptional activator of p21 in melanoma. In p53 mutated cell lines we detected a marked 
reduction in p21 mRNA levels compared to p53 wild-type cell lines. However, p21 mRNA 
could still be detected with Real-Time RT-PCR in these cell lines, suggesting that other 
transcription factors also contribute to transcriptional regulation of p21. In the next chapter, 
p53-independent transcriptional regulation of p21 will be discussed.   
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4.3 p53-independent transcriptional regulation of p21  
The promoter region of p21 has been characterized and a number of binding sites for 
various transcription factors have been previously described [110]. A list over potential 
regulators of p21 transcription is shown in Table 1.8, section 1.3.1.  Preferably, all of these 
potential regulators of p21 should be screened at the protein level with additional gain- and 
loss of function studies to elucidate their possible role in p21 transcriptional regulation of 
melanoma. However, due to limited number of antibodies available, combined with the time 
limitation of this study, we chose to validate around 17 potential transcription factors at the 
transcriptional level in 17 cell lines. The mRNA expression levels of these transcription 
factors where then compared against the p21 mRNA expression levels. Our results showed 
that none of the transcriptional regulators investigated demonstrated any obvious positive or 
negative correlation with the p21 mRNA expression levels throughout the panel (figure 3.8, 
section 3.4.1). To further address whether some of these potential regulators have a role in 
p21 transcriptional regulation of our melanoma cell panel, we used small molecular chemical 
inhibitors against the A375 and the SKMEL28 cell lines. Due to the large number of potential 
p21 regulators investigated, 4 genes (TBX2, AP-2, c-Myc and MITF) were chosen for 
further analysis (figure 3.9, section 3.4.2). The A375 and the SKMEL28 cell lines were 
chosen as they represent both wild-type and mutated p53, respectively. Furthermore, both are 
BRAF
V600E
 mutated and A375 contains low levels of MITF protein, while SKMEL28 has 
high levels of MITF protein (unpublished data). After analyzing our data we could not detect 
any solid correlation between p21 mRNA levels and the four potential regulators selected in 
either the A375 or the SKMEL28 cell line. In the SKMEL28 cell line, which is mutated for 
p53, but still have some p21 expression, we found indications of an inverse correlation 
between p21 mRNA expression and TBX2 after different inhibitor treatments. Nevertheless, 
due to the small changes in p21 mRNA levels after inhibitor treatments and with respect to 
the observed error bars (standard deviation values), this result needs further validation. 
Validation by the use of gain- and loss of function methods would contribute to confirm 
TBX2’s role in p21 transcriptional regulation. The inhibitory effect of TBX2 upon the p21 
promoter has also been described previously in the literature [111]. When comparing p21 
mRNA levels with AP-2 and c-Myc after Plexxikon and UO126 treatments, we found a 
negative and a positive correlation, respectively. This is contradictory compared to previous 
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studies, describing AP-2 as an activator of p21 transcriptional regulation, while c-Myc have 
been found to be a repressor [28, 44]. In conclusion, this latter result clearly shows that loss 
and gain of function tools, which offer specificity towards the gene of interest, is required for 
verifying the role of each transcription factors that binds to the promoter. Moreover, the use of 
small molecular chemical inhibitors offers usually only unspecific screening that can 
contribute to find potential regulatory genes of interest. However, small molecular chemical 
inhibitors are an important tool when the aim is to disclose how pathway signaling contributes 
to p21 regulation, which is further discussed in the next chapter. 
 
4.4 Signal pathway involved in p21 regulation 
Previous reports suggest that p21 expression can be controlled transcriptionally, post-
transcriptionally, translationally, post-translationally and by epigenetic mechanisms. In our 
study, we used small molecular chemical inhibitors against the MAPK- and cAMP pathway. 
The reason for this was to investigate how p21 expression is regulated by these pathways that 
are essential for melanoma development. Both the MAPK- and the cAMP pathway are often 
deregulated in melanoma by mutations in e.g. MCR-1 and BRAF
V600E
. These mutations will 
again increase the risk for melanoma development. For the MAPK-pathway we used 
inhibitors against BRAF
V600E 
(Plexxikon), MEK1/2 (UO126), and RSK1-4 (BI-D1870) in two 
metastatic cell lines, A375 and SKMEL28. 
 
Our results showed that p21 protein levels were 
down-regulated after Plexxikon and UO126 treatment in both cell lines. In contrast, BI-D1870 
treatment did not seem to influence p21 protein levels significantly. This result was 
unexpected since all the inhibitors used, targeted the same signal pathway (MAPK). At the 
current stage we do not have any decent explanation for the observed result. The PKA 
inhibitor H-89 showed comparable effects upon p21 protein levels as the BI-D1870 inhibitor, 
or at best a minor up-regulation of p21 in the SKMEL28 cell line. When we investigated 
phospho-ERK, phospho-AKT and phospho-STAT1 protein levels and compared these levels 
against the p21 protein levels, none of these “key” pathway proteins correlated perfectly to 
p21 protein levels for all treatment combinations. However, all of them showed more or less 
good correlation with p21 protein levels when comparing only the single treatments (figure 
3.10, section 3.5). The best correlation was however observed between p53 and p21 protein 
levels as previously shown. Of note, the MITF protein levels show a negative correlation with 
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p21 protein levels after single treatments in SKMEL28 (MITF positive cell line, in contrast to 
A375). This is in agreement with previous reports, showing the inhibitory effects of TBX2 
(which is a MITF target) upon p21 transcriptional regulation in melanoma [112]. In 
conclusion, our results showed that down-regulation of phospho-ERK by e.g. Plexxikon 
results in decreased levels of p21 protein, while up-regulation of phospho-ERK by H-89 has 
the opposite effect. This is in agreement with other reports, showing induction of the 
senescence markers (p21 and p16) in e.g. melanocytes when the MAPK pathway is 
overstimulated [64, 94]. How p21 and senescence can be used as therapeutic approach is 
discussed in the next chapter. 
 
4.5 p21 as a therapeutic target 
p21 was originally identified as an inhibitor of cyclin-dependent kinases, a marker of 
cellular senescence and a mediator of p53 in growth suppression. p21 is required for 
appropriate cell cycle progression and plays a role in apoptosis, DNA repair, senescence, and 
induced pluripotent stem cell reprogramming. In fact, p21 was first identified as an 
overexpressed marker in senescent cells [113], to inhibit cell cycle progression. Several 
studies showed that p21 is up-regulated during oncogenic Ras-induced cellular senescence 
and inhibits Ras-induced transformation [114, 115]. It has been stated that the overexpression 
of p21, p53, pRB, or p16 is generally sufficient to induce a senescence growth arrest and 
consequent tumor suppression [116]. Activating the program of senescence in tumor cells 
seems an attractive approach to cancer treatment. Senescence-oriented therapeutic strategies 
may include development of drugs that will induce tumor cell senescence by up-regulating 
p21 (which, unlike p16, is almost never inactivated in tumors) or p21-inducible senescence-
promoting genes [117, 118]. Identification of senescence-associated growth-inhibitory genes 
makes it possible to develop high-throughput screening systems for agents that induce such 
genes for instance p300 and c-Myc, which can regulate and arrest senescence respectively in 
cancer cells by manipulation of p21 [112, 117]. Thus, the elucidation of the biological aspects 
of tumor cell senescence offers plausible approaches for development of novel therapeutic 
strategies to stop the growth of tumor cells. 
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Conclusions 
The present study showed that p21 mRNA expression was present in all cell lines in 
the melanoma cell panel. Epigenetic silencing of p21 therefore does not seem to play an 
important role in human melanoma cell lines. Our results revealed a strong correlation 
between p21 mRNA and protein levels; the exception was the LOX cell line. This result 
implies that post-transcriptional regulation by miRNA activity is less important in our cell 
panel. After screening the human melanoma cell panel for p21 expression at both mRNA and 
protein level, we compared expression levels against the disease stage and the mutational 
background. From these data we could not observe any correlation in expression between 
primary (RGP/VGP) and metastatic stages of the disease. In contrast, we detected a strong 
correlation between p21 expression and the mutational status of p53. This was further 
investigated by the use of various chemical inhibitors against the MAPK- and cAMP- 
pathways. These data showed that changes in p21 protein amount after treatment followed the 
changes detected in p53 protein amount. The latter result implies strong co-regulation 
between the two genes and is in agreement with previous reports. We also measured the 
expression levels of a number of transcription factors that previously been known to regulate 
p21 at the transcriptional level. However, when comparing these results against the p21 
mRNA levels we could not detect any correlation. We then selected some of these genes for 
further manipulations by chemical inhibitors. Our results implied that TBX2 expression after 
treatment is negatively correlated with p21 in the SKMEL28 cell line. However, to verify this 
result, a more specific method involving loss- and gain of function of the particular gene of 
interest should be utilized. Although, many factors and mechanisms have been identified to 
regulate p21 expression, other factors are yet to be identified. A number of transcription 
factors have been found to bind to the p21 promoter, the role of each need to be further 
investigated to understand their effects upon p21 mRNA production. 
 
 
 
66 
 
 
 
Future perspectives 
The results obtained in this study, raised new questions that would be interesting to 
pursue in the future. To what degree do p53 control p21 transcription in melanoma is still not 
fully understood. In mutated p53 cell lines we still detect p21 mRNA, but at a reduced level 
compared to normal p53. Does this mean that other transcription factors contribute to the 
transcriptional expression of p21, or can it be explained by other mechanisms? As known 
from the literature, mutant p53 is not the same as a missing p53. Mutant p53 have been found 
to function as an oncogene, the opposite of normal p53, which is a tumor-suppressor. Whether 
these new functions affect p21 mRNA transcriptional regulation is unknown. However, it 
would be interesting to investigate whether mutant p53 behaves like non-existing p53 in 
respect to p21 transcriptional regulation. Furthermore, the effect of each of the transcription 
factors and their co-factors that bind to the p21 promoter is unknown. To what extent do they 
control p21 in melanoma? To what degree is the promoter regulation cell-type specific, is it 
influenced by the microenvironment, or is it mainly controlled by the mutational status of the 
tumor cells. Due to the limited time span of this project many questions regarding p21 
transcriptional regulation remain unanswered and further analysis and validation are 
necessary. For future investigations regarding the effect of the various transcriptional 
regulators of p21 transcription, molecular approaches like siRNA and mRNA transfections 
would be useful. With these tools it would be possible to study both gain- and loss of function 
of the gene of interest. Other relevant inquiries that should be addressed, is the importance of 
p21 in melanoma progression. Is manipulation of p21 a suitable target to control tumor 
progression? Is it possible to manipulate p21 to induce cell senescence in melanoma and 
exploit this inherited mechanism in a therapeutic setting?  
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APPENDIX A 
Buffers and solutions used in the study 
Table A1. Complete growth medium supplements. 
Supplement Concentration Per 500 ml RPMI 1640 
without L-Glutamine 
Fetal bovine serum 10% 50 ml 
glutaMAX 2 mM 5.5 ml of 200 mM stock 
 
Table A2. Freeze medium supplements. 
Supplement Concentration Per 50 ml complete 
growth medium 
Fetal bovine serum 20% 5 ml 
DMSO 10% 5 ml  
 
Table A3. Preparation of protein samples for gel electrophoresis. 
 
 
 
 
 
Table A4. Contents of wash buffer 0.1 % TBS-T (TBS with 0.1% Tween 20). 
Compound Volume (ml) 
5 M NaCl  27.5  
1 M Tris-HCl PH 7.5 20 
20 % Tween 20 5 
ddH2O To 1000 
Compound Volume (l) 
Sample X 
de-ionized water to 6.5 
NuPAGE LDS sample buffer (4X) 2.5 
NuPAGE Reducing Agent (10X) 1 
Total 10 
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APPENDIX B 
Real time PCR data 
 Table B1. Primer sequences for qPCR. 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
CBX7 TGG GTT TCG GAC CTC TCT 
T 
CGT CAT GGC CTA CGA GGA 
CDC6 GTGTTGCATAGGTTGTCATC
G 
CCTGTTCTCCTCGTGTAAAAG
C 
CDKN1A 
(p21) 
CGA-AGT-CAG-TTC-CTT-
GTG-GAG 
CAT-GGG-TTC-TGA-CGG-ACA-
T 
CITED2 CAG CAC ATA GAG GGG ACC 
TT 
AGG GGA AAT AAA AGG GAA 
CG 
c-Myc TAACGTTGAGGGGCATCG GCTGCTTAGACGCTGGATTT 
ELK4 TGA ATG GCC CAT GAC TGT 
T 
CAG TCC TGT TGC TCC CCT 
AA 
EP300 AAA CAG CCA TCA CAG ACG 
AA 
GAT CTG TGT CCT TCA CCA 
TGA G 
ID2 GTT GTT GTT GTG CAA AGA 
ATA AAA G 
TGT CAA ATG ACA GCA AAG 
CAC 
ID3 CCT CCG GCA GGA GAG GTT CAT CTC CAA CGA CAA AAG 
GAG 
MITF-m CAT-TGT-TAT-GCT-GGA-
AAT-GCT-AGA 
GCT AAA GTG GTA GAA AGG 
TAC TGC 
PRMT6 CCC ACG TCC AGT ACC GTC 
T 
ACC GCC TGG GTA TCC TTC 
RPLPO TCG-AAC-ACC-TGC-TGG-
ATG-AC 
CGC-TGC-TGA-ACA-TGC-TCA-
AC 
SALL2 ACC AGC TGA GCA GAA 
AGG TC 
ATT GCA GCC TAG CCA AAA 
AG 
SP1 TCC ACC TGC TGT GTC ATC 
AT 
CTA TAG CAA ATG CCC CAG 
GT 
SP3 GGT GAC GGC TGA GTG TCC CAG CAGCAG CAA CAG CAC 
TBP GCC-CGA-AAC-GCC-GAA-
TAT 
CGT-GGC-TCT-CTT-ATC-CTC-
ATG-A 
TBX2 CACTAGTGGCGGGCAAAG GCACATGCTGGCATCTCA 
TBX3 ACT GCA GGG TGA GCT GTT 
TT 
AAA AAT AGA CAA CAA CCC 
TTT TGC 
75 
 
 
 
TFAP2A 
(AP-2alpha) 
AGG GGA GAT CGG TCC TGA ACA TGC TCC TGG CTA CAA 
AAC 
TFAP2C 
(AP-
2gamma) 
GGG GCT GTA GAG GTG CTG CGA AGA GGA CTG CGA GGA 
 
Primer efficiencies 
a)                                                                                                                       b) 
 
 
Figure B2. Generating a standard curve to assess reaction optimization. a) A standard curve 
was generated using a 10-fold dilution of the MEWO as a template amplified on the iCycler 
iQ real-time system. Each dilution was assayed in duplicate. The equation for the regression 
line and the R value are shown in the graph. b) Dilution series and the Ct-values.  
 
Amplification efficiency, E, is calculated from the slope of the standard curve using 
the following formula:  
E= 10
-1/slope
 
Amplification efficiency is frequently presented as a percentage, that is, the percent of 
template that was amplified in each cycle:               
% Efficiency = (E-1) × 100% 
For the example shown in figure B2: 
E (SP1) = 10
-(1/-3.325) 
= 1.998 
% Efficiency (SP1) = (1.998-1) × 100% = 99.87% 
y = -3.325x + 37.495 
R² = 0.9903 
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Log Starting Quantity, copy  number 
Sample (ng/µl) Ct  mean 
1) 0.004 34.8 
2) 0.04 30.3 
3) 0.4 27.2 
4) 4 23.95 
5) 40 21.35 
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At the end of each cycle, the amplicon copy number increased 1.998-fold, or 99.87% 
of the template that was amplified.  
 
Table B3. Primer efficiencies for qPCR.  
Gene Primer efficiency 
CDC6 98.03% 
CITED2 100.08% 
c-Myc 102.2% 
ELK4 97.63% 
EP300 101.99% 
ID2 102.87% 
MITF-m 93.8% 
p21 95.2% 
RPLPO 100.1% 
SP1 99.87% 
SP3 92.17% 
TBP 96.7% 
TBX2 105.35% 
TBX3 101.99% 
TFAP2A (AP-2alpha) 101.78% 
TFAP2C (AP-2gamma) 98.43% 
 
 
For the primers with Ct-value more than 33 in serially diluted samples, the efficiency 
was calculated after omitting Ct mean ≥ 33 and they need to be checked on another cell line in 
further experiments. 
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Western blotting data 
Table B4. Standard curve of reference protein calculations. 
Reference protein (µg) Reference protein (µl) ddH2O (µl) 
0 0 10 
1 0.73 9.27 
2 1.46 8.54 
3 2.19 7.81 
4 2.92 7.08 
5 3.65 6.35 
 
The average absorbance from triplicates was calculated the background absorbance 
was subtracted. Using linear regression from the standard curve, an equation was deduced that 
could be used to calculate the protein concentration of the samples (exemplified in figure B5). 
 
Figure B5. A representative graph on standard curve for the calculation of protein 
concentrations. The measured absorbance is plotted as a function of the reference protein 
concentration. The equation is found by linear regression and is used to calculate protein 
concentrations of the samples. R
2 
indicate how well the data fit into the linear regression line.  
y = 0.0533x 
R² = 0.9906 
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APPENDIX C 
Supplementary data 
  Control                                       PLX4032 (Plexxikon)               UO126 (MEK1/2) 
  H-89 (PKA)                               BI-D1870 (RSK) 
  
  Control                                      PLX4032 (Plexxikon)                 UO126 (MEK1/2) 
   
  H-89 (PKA)                               BI-D1870 (RSK) 
 
 
 
 
A375 
SKMEL28 
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Cell lines 
CBX7 mRNA levels in the melanoma cell panel 
Figure C1. Microscopy pictures of A375 and SKMEL28 cell lines when treated with 10 µM 
Plexxikon, MEK1/2, PKA, RSK inhibitors. The pictures shown are representative for three 
biological parallels. 
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CITED2 mRNA levels in the melanoma cell panel 
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PRMT6 mRNA levels in the melanoma cell panel 
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CEBPA mRNA levels in the melanoma cell panel 
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ELK4 mRNA levels in the melanoma cell panel 
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AP-2γ mRNA levels in the melanoma cell panel 
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ID2 mRNA levels in the melanoma cell panel 
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SP3 mRNA levels in the melanoma cell panel 
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ID3 mRNA levels in the melanoma cell panel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-7
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
6
7
W
M
1
15
W
M
1
36
6
W
M
9
83
A
W
M
1341B
W
M
8
52
W
M
2
66
-4
W
M
9
M
EW
O
FEM
X
-I
FEM
X
-V
SK
M
EL2
8
W
M
1382
W
M
2
39
A
A
375
LO
X
W
M
45.1
VGP
Metastatic
m
R
N
A
 l
e
v
e
ls
 n
o
rm
a
li
z
e
d
 t
o
 W
M
3
5
 
 (
L
O
G
2
) 
Cell lines 
SALL2 mRNA levels in the melanoma cell panel 
84 
 
 
 
 
 
Figure C2. Real-time RT-PCR data showing mRNA expression levels of CITED2, CBX7, 
PRMT6, CEBPA, ELK4, AP-2γ, SP-3, ID2, ID3, SALL2, TBX3, CDC6 in the melanoma cell 
panel. Data is presented as LOG2 and cell lines were normalized to WM35 (a cell line from 
the RGP stage). Blue bars represent VGP cell lines, while grey bars represent metastatic cell 
lines. Error bars represent standard deviation (SD) from three biological parallels. 
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TBX3 mRNA levels in the melanoma cell panel 
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